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A B S T R A C T
Background
The lateral flow urine lipoarabinomannan (LF-LAM) assay Alere Determine™ TB LAM Ag is recommended by the World Health Organization
(WHO) to help detect active tuberculosis in HIV-positive people with severe HIV disease. This review update asks the question, "does new
evidence justify the use of LF-LAM in a broader group of people?”, and is part of the WHO process for updating guidance on the use of
LF-LAM.
Objectives
To assess the accuracy of LF-LAM for the diagnosis of active tuberculosis among HIV-positive adults with signs and symptoms of tuberculo-
sis (symptomatic participants) and among HIV-positive adults irrespective of signs and symptoms of tuberculosis (unselected participants
not assessed for tuberculosis signs and symptoms).
The proposed role for LF-LAM is as an add on to clinical judgement and with other tests to assist in diagnosing tuberculosis.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register; MEDLINE, Embase, Science Citation Index, Web of Science,
Latin American Caribbean Health Sciences Literature, Scopus, the WHO International Clinical Trials Registry Platform, the International
Standard Randomized Controlled Trial Number Registry, and ProQuest, without language restriction to 11 May 2018.
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Selection criteria
Randomized trials, cross-sectional, and observational cohort studies that evaluated LF-LAM for active tuberculosis (pulmonary and extra-
pulmonary) in HIV-positive adults. We included studies that used the manufacturer's recommended threshold for test positivity, either
the updated reference card with four bands (grade 1 of 4) or the corresponding prior reference card grade with five bands (grade 2 of 5).
The reference standard was culture or nucleic acid amplification test from any body site (microbiological). We considered a higher quality
reference standard to be one in which two or more specimen types were evaluated for tuberculosis diagnosis and a lower quality reference
standard to be one in which only one specimen type was evaluated.
Data collection and analysis
Two review authors independently extracted data using a standardized form and REDCap electronic data capture tools. We appraised the
quality of studies using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool and performed meta-analyses to esti-
mate pooled sensitivity and specificity using a bivariate random-effects model and a Bayesian approach. We analyzed studies enrolling
strictly symptomatic participants separately from those enrolling unselected participants. We investigated pre-defined sources of hetero-
geneity including the influence of CD4 count and clinical setting on the accuracy estimates. We assessed the certainty of the evidence
using the GRADE approach.
Main results
We included 15 unique studies (nine new studies and six studies from the original review that met the inclusion criteria): eight studies
among symptomatic adults and seven studies among unselected adults. All studies were conducted in low- or middle-income countries.
Risk of bias was high in the patient selection and reference standard domains, mainly because studies excluded participants unable to
produce sputum and used a lower quality reference standard.
Participants with tuberculosis symptoms
LF-LAM pooled sensitivity (95% credible interval (CrI) ) was 42% (31% to 55%) (moderate-certainty evidence) and pooled specificity was
91% (85% to 95%) (very low-certainty evidence), (8 studies, 3449 participants, 37% with tuberculosis).
For a population of 1000 people where 300 have microbiologically-confirmed tuberculosis, the utilization of LF-LAM would result in: 189
to be LF-LAM positive: of these, 63 (33%) would not have tuberculosis (false-positives); and 811 to be LF-LAM negative: of these, 174 (21%)
would have tuberculosis (false-negatives).
By clinical setting, pooled sensitivity was 52% (40% to 64%) among inpatients versus 29% (17% to 47%) among outpatients; and pooled
specificity was 87% (78% to 93%) among inpatients versus 96% (91% to 99%) among outpatients. Stratified by CD4 cell count, pooled
sensitivity increased, and specificity decreased with lower CD4 cell count.
Unselected participants not assessed for signs and symptoms of tuberculosis
LF-LAM pooled sensitivity was 35% (22% to 50%), (moderate-certainty evidence) and pooled specificity was 95% (89% to 96%), (low-cer-
tainty evidence), (7 studies, 3365 participants, 13% with tuberculosis).
For a population of 1000 people where 100 have microbiologically-confirmed tuberculosis, the utilization of LF-LAM would result in: 80
to be LF-LAM positive: of these, 45 (56%) would not have tuberculosis (false-positives); and 920 to be LF-LAM negative: of these, 65 (7%)
would have tuberculosis (false-negatives).
By clinical setting, pooled sensitivity was 62% (41% to 83%) among inpatients versus 31% (18% to 47%) among outpatients; pooled speci-
ficity was 84% (48% to 96%) among inpatients versus 95% (87% to 99%) among outpatients. Stratified by CD4 cell count, pooled sensitivity
increased, and specificity decreased with lower CD4 cell count.
Authors' conclusions
We found that LF-LAM has a sensitivity of 42% to diagnose tuberculosis in HIV-positive individuals with tuberculosis symptoms and 35% in
HIV-positive individuals not assessed for tuberculosis symptoms, consistent with findings reported previously. Regardless of how people
are enrolled, sensitivity is higher in inpatients and those with lower CD4 cell, but a concomitant lower specificity. As a simple point-of-
care test that does not depend upon sputum evaluation, LF-LAM may assist with the diagnosis of tuberculosis, particularly when a sputum
specimen cannot be produced.
17 October 2019
Up to date
All studies incorporated from most recent search
All studies identified during the most recent search (11 May, 2018) have been incorporated in the review, and no ongoing studies identified.
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P L A I N   L A N G U A G E   S U M M A R Y
Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV
Why is improving the diagnosis of tuberculosis important?
Tuberculosis causes more deaths in people living with HIV than any other disease. The lateral flow urine lipoarabinomannan assay (LF-LAM,
Alere Determine™ TB LAM Ag assay) is a World Health Organization-recommended rapid test to assist in detection of active tuberculosis in
HIV-positive people with severe HIV disease. Rapid and early tuberculosis diagnosis may allow for prompt treatment and alleviate severe
illness and death. An incorrect tuberculosis diagnosis may result in anxiety and unnecessary treatment.
What is the aim of this review?
To find out how accurate LF-LAM is for diagnosing tuberculosis in HIV-positive people with tuberculosis symptoms (symptomatic partici-
pants) and those not assessed for tuberculosis symptoms (unselected participants). This is an update of the 2016 Cochrane Review.
What was studied in this review?
LF-LAM is a commercially available point-of-care test that detects lipoarabinomannan (LAM), a component of the bacterial cell walls,
present in some people with active tuberculosis. The test is simple and shows results in 25 minutes. LF-LAM results were measured against
culture or molecular tests (benchmark).
What are the main results of this review?
Fifteen studies: eight studies evaluated LF-LAM for tuberculosis among symptomatic participants and seven studies among unselected
participants. All studies were conducted in low- or middle-income countries.
Tuberculosis diagnosis among symptomatic participants: LF-LAM registered positive in 42% (sensitivity) of people who actually had tu-
berculosis and did not register positive in 91% of people who were actually negative (specificity).
Tuberculosis diagnosis among unselected participants: LF-LAM sensitivity was 35% and specificity 95%.
How confident are we in the review’s results?
Several studies excluded participants who could not produce sputum and most studies relied on a lower quality benchmark. Few studies
and participants were included in some analyses and only one study was conducted outside of sub-Saharan Africa. Results should be
interpreted with caution.
What do the results mean?
Among symptomatic participants, in theory, for a population of 1000 people where 300 have microbiologically-confirmed tuberculosis,
the utilization of LF-LAM would result in: 189 to be LF-LAM positive: of these, 63 (33%) would not have tuberculosis (false-positives); and
811 to be LF-LAM negative: of these, 174 (21%) would have tuberculosis (false-negatives).
Among unselected participants, in theory, for a population of 1000 people where 100 have microbiologically-confirmed tuberculosis, the
utilization of LF-LAM would result in: 80 to be LF-LAM positive: of these, 45 (56%) would not have tuberculosis (false-positives); and 920 to
be LF-LAM negative: of these, 65 (7%) would have tuberculosis (false-negatives).
Who do the review’s results apply to?
HIV-positive people with tuberculosis symptoms and those not assessed for tuberculosis symptoms.
What are the implications of this review?
LF-LAM has sensitivity around 40% to detect tuberculosis. As the test does not require sputum collection, LF-LAM may be the only way to
diagnose tuberculosis when sputum cannot be produced.
How up-to-date is this review?
To 11 May 2018.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   LF-LAM for symptomatic participants
Review question: what is the diagnostic accuracy of LF-LAM for the diagnosis of active tuberculosis in HIV-positive adults with signs and symptoms of tuberculosis?
Studies: cross-sectional studies and randomized controlled trials
Participants: HIV-positive adults with tuberculosis signs and symptoms
Setting: all settings (inpatient and outpatient)
Index test: LF-LAM
Threshold for index tests: manufacturer's recommended threshold for positivity i.e. grade 1 of 4 (revised reference card) or the corresponding grade 2 of 5 (prior reference
card)
Reference standard: microbiological (mycobacterial culture and/or nucleic acid amplification test)
Role: an add on to clinical judgement and with other tests to assist in tuberculosis diagnosis
Pooled sensitivity (95%CrI): 42% (31% to 55%); pooled specificity (95% CrI): 91% (85% to 95%)
Number of results per 1000 participants tested (95% CrI)Test result
Prevalence 1%
Typically seen in asymptomatic
persons in outpatient settings
Prevalence 10%
Typically seen in symptomatic per-
sons in all settings
Prevalence 30%
Typically seen in seriously ill per-
sons in inpatient settings
Number of
participants
(studies)
Certainty of
the evidence
(GRADE)
True positives 4 (3 to 6) 42 (31 to 55) 126 (93 to 165)
False nega-
tives
6 (4 to 7) 58 (45 to 69) 174 (135 to 207)
1277 (8) ⊕⊕⊕⊝
MODER-
ATEa,b,c,d
True negatives 901 (842 to 941) 819 (765 to 855) 637 (595 to 665)
False positives 89 (49 to 148) 81 (45 to 135) 63 (35 to 105)
2172 (8) ⊕⊝⊝⊝
VERY LOWc,e,f
Abbreviations: Crl: credible interval.
Explanations
aAs assessed by QUADAS-2, in the patient selection domain, we judged six studies (75%) at high risk of bias because they did not avoid inappropriate exclusions. We down-
graded one level for risk of bias.
bFor individual studies, sensitivity estimates ranged from 23% to 68%. We thought that differences in enrolment criteria (different populations targeted) or CD4 count could
explain in part the heterogeneity. We did not downgrade for inconsistency.
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cThe median tuberculosis prevalence in the studies was 42% and thus the results tend to be more applicable to settings with a higher tuberculosis prevalence. For tubercu-
losis prevalence of 1% and 10%, whether or not to downgrade remains unclear. It is possible the test will perform differently at lower prevalences. We did not downgrade for
indirectness.
dWe thought the 95% CrIs around true positives and false negatives would likely not lead to different decisions depending on which credible limits are assumed. We did not
downgrade for imprecision.
eAs assessed by QUADAS-2, in the reference standard domain, we judged seven studies (88%) at high risk of bias because we thought the reference standard used was un-
likely to correctly classify the target condition. We downgraded two levels for risk of bias.
fWe thought the 95% CrIs around true negatives and false positives would likely lead to different decisions depending on which credible limits are assumed. We downgrad-
ed one level for imprecision.
GRADE certainty of evidence (GRADEpro 2015; Balshem 2011)
High: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate: we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially
different.
Low: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.
The table displays normalized frequencies within a hypothetical cohort of 1000 patients at three different prevalences of tuberculosis (pre-test probabilities): 1%, 10% and
30%. Credible limits (Crls) were estimated based on those around the point estimates for pooled sensitivity and specificity.
Note: the results on this table should not be interpreted in isolation from the results of the individual included studies contributing to each summary test accuracy measure.
These are reported in the main body of the text of the review.
 
 
Summary of findings 2.   LF-LAM for unselected participants
Review question: what is the diagnostic accuracy of LF-LAM for the diagnosis of active tuberculosis in HIV-positive adults irrespective of signs and symptoms of tuberculo-
sis?
Studies: cross-sectional studies and randomized controlled trials
Participants: HIV-positive unselected adults not assessed for signs and symptoms of tuberculosis i.e. irrespective of symptoms
Setting: all settings (inpatient and outpatient)
Index test: LF-LAM
Threshold for index tests: manufacturer's recommended threshold for positivity i.e. grade 1 of 4 (revised reference card) or the corresponding grade 2 of 5 (prior reference
card)
Reference standard: microbiological (mycobacterial culture and/or nucleic acid amplification test)
Role: an add on to clinical judgement and with other tests to assist in tuberculosis diagnosis
Pooled sensitivity (95% CrI): 35% (22% to 50%); pooled specificity (95% CrI): (89% to 98%)
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Number of results per 1000 participants tested (95% CrI)Test result
Prevalence 1%
Typically seen in asymptomatic
persons in outpatient settings
Prevalence 10%
Typically seen in symptomatic per-
sons in all settings
Prevalence 30%
Typically seen in seriously ill per-
sons in inpatient settings
Number of
participants
(studies)
Certainty of
the evidence
(GRADE)
True positives 3 (2 to 5) 35 (22 to 50) 105 (66 to 150)
False nega-
tives
7 (5 to 8) 65 (50 to 78) 195 (150 to 234)
432 (7) ⊕⊕⊕⊝
MODER-
ATEa,b,c
True negatives 941 (881 to 970) 855 (801 to 882) 665 (623 to 686)
False positives 49 (20 to 109) 45 (18 to 99) 35 (14 to 77)
2933 (7) ⊕⊕⊝⊝
LOWd,e,f
Abbreviations: Crl: Credible interval.
Explanations
aAs assessed by QUADAS-2, in the patient selection domain, we judged four studies (57%) at high risk of bias because they did not avoid inappropriate exclusions. We down-
graded one level for risk of bias.
bFor individual studies, sensitivity ranged from 0% to 67%. We thought that the percentage of patients with tuberculosis symptoms or differences in CD4 count could ex-
plain in part the heterogeneity. One study, LaCourse 2016, with sensitivity of 0% differed from the other studies by including a) a population of exclusively pregnant women
attending an antenatal care setting, b) a low proportion of symptomatic participants (19%), c) a low tuberculosis prevalence (1%), and d) a high median CD4 cell count (437
cells per µL). One study, Thit 2017, with sensitivity 67% differed from the other studies by being conducted in Myanmar, and was the only study included in this review that
evaluated LF-LAM in a setting outside sub-Saharan Africa. We did not downgrade for inconsistency.
cWe thought the 95% CrI around true positives and false negatives would likely not lead to different decisions depending on which credible limits are assumed. We did not
downgrade for imprecision.
dAs assessed by QUADAS-2, in the reference standard domain, we judged five studies (71%) at high risk of bias because we thought the reference standard used was unlikely
to correctly classify the target condition. We downgraded one level for risk of bias.
eFor individual studies, specificity ranged from 67% to 99%. Eighty-six per cent (6/7) of the included studies had specificity of 94% or higher. One study, Thit 2017, with
specificity 67% differed from the other studies by being conducted in Myanmar, and is the only study included in this review that evaluated LF-LAM in a setting outside sub-
Saharan Africa. We did not downgrade for inconsistency.
fWe thought the wide 95% Crls around true negatives and false positives would lead to different decisions depending on which credible limits are assumed. We downgraded
one level for imprecision.
GRADE certainty of evidence (GRADEpro 2015; Balshem 2011)
High: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate: we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially
different.
Low: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.
The table displays normalized frequencies within a hypothetical cohort of 1000 patients at three different prevalences of tuberculosis (pre-test probabilities): 1%, 10% and
30%. Credible limits (Crls) were estimated based on those around the point estimates for pooled sensitivity and specificity.
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Note: the results on this table should not be interpreted in isolation from the results of the individual included studies contributing to each summary test accuracy measure.
These are reported in the main body of the text of the review.
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B A C K G R O U N D
Tuberculosis is an infectious airborne disease caused by the bacil-
lus Mycobacterium tuberculosis (M tuberculosis). In 2017, an esti-
mated 10.0 million people developed tuberculosis disease of which
920,000 (9%) occurred among people living with HIV (WHO Glob-
al Tuberculosis Report 2018). Although the number of tuberculo-
sis deaths has fallen since 2000, tuberculosis was responsible for
1.6 million deaths in 2017 (WHO Global Tuberculosis Report 2018),
and tuberculosis has surpassed HIV as the world's leading cause
of death from an infectious disease. Among people living with HIV,
tuberculosis is the major cause of hospitalisation and in-hospital
death despite increased access to antiretroviral treatment (ART)
(Ford 2016). A systematic review of the prevalence of tuberculo-
sis identified at autopsy in resource-limited settings, suggests that
tuberculosis is responsible for up to 40% of all HIV-related deaths
and that tuberculosis often is disseminated and undiagnosed at the
time of death (Gupta 2015). Globally in 2017, only 51% of the in-
cident tuberculosis cases were reported among people living with
HIV (WHO Global Tuberculosis Report 2018). However, most deaths
from tuberculosis are preventable if the disease is detected early
and effectively treated. Overall, it is estimated that 45 million lives
were saved between 2000 and 2017 through effective diagnosis and
treatment (WHO Global Tuberculosis Report 2018).
Geographically, HIV and tuberculosis are often concentrated in ar-
eas of poverty with limited resources for diagnosis, treatment, and
prevention of tuberculosis. Most of the 30 high tuberculosis/HIV
burden countries are situated in sub-Saharan Africa where HIV-
infection represents a major driver of the tuberculosis epidemic
(WHO Global Tuberculosis Report 2018). HIV-positive individuals
have a 20- to 37-fold increased risk of developing tuberculosis com-
pared to HIV-negative individuals (Getahun 2010). The risk of tuber-
culosis increases with decreasing CD4 cell count, and remains ele-
vated throughout the course of HIV (Gupta 2012; Lawn 2009).
Tuberculosis predominantly affects the lungs (pulmonary tubercu-
losis), but can affect most parts of the body, such as the lymph
nodes, pleura, brain, or spine (extrapulmonary tuberculosis). Ex-
trapulmonary tuberculosis represented 14% of the incident tuber-
culosis cases notified in 2017 (WHO Global Tuberculosis Report
2018). In comparison with HIV-negative people, HIV-positive peo-
ple have higher rates of extrapulmonary tuberculosis or mycobac-
teraemia (tuberculosis bloodstream infection) (Pai 2016; Shivakoti
2017). Signs and symptoms of tuberculosis in people living with
HIV vary depending on the progression of immunodeficiency and
involved site(s). Complaints are often non-specific such as fever,
weight loss, and fatigue. A cough for longer than two weeks is a
common distinguishing feature of tuberculosis that prompts diag-
nostic testing for tuberculosis in people who are HIV negative, but is
present in less than a third of people with tuberculosis who are HIV
positive (Cain 2010). Similarly, radiographic features of tuberculo-
sis in people living with HIV may be misleading or atypical. Where-
as upper lobe cavitary lesions are often seen in HIV-negative peo-
ple with tuberculosis, such lesions are less common in HIV-positive
people with tuberculosis (Cain 2010). Identifying those who war-
rant further testing for tuberculosis can therefore be challenging.
Tuberculosis diagnosis further relies heavily on a sputum-based
test strategy that may have limited accuracy as well as applicabili-
ty among a population that may be sputum scarce and frequently
has extrapulmonary and disseminated tuberculosis disease. More-
over, people living with HIV often have paucibacillary tuberculosis
disease that makes diagnosis of tuberculosis by smear microscopy,
nucleic acid amplification tests (NAATs), and culture less sensitive.
Non-sputum-based point-of-care tuberculosis diagnostic tests are
highly desired to improve tuberculosis case detection in people liv-
ing with HIV and ensure timely treatment (WHO TTP 2014). Desired
characteristics of such a test would include minimal or non-inva-
sive sample collection, short time to result (under one hour), and
ability to implement the test without need for special instruments,
electricity, or specimen preparation (WHO TTP 2014).
Detection of mycobacterial antigen in urine has attracted great at-
tention over time. Urine-based antigen testing would allow for a tu-
berculosis diagnosis that is non-site specific. In addition, urine is
easy to collect and store, and lacks the infection control risks as-
sociated with sputum collection. Multiple platforms have been de-
veloped to detect lipoarabinomannan (LAM), a component of my-
cobacterial cell walls, initially as enzyme-linked immunosorbent
(ELISA) assays that were evaluated in several clinical settings (Min-
ion 2011). Later, the lateral flow urine lipoarabinomannan (LF-LAM,
Alere Determine TB-LAM assay) was developed as a simple point-
of-care test for diagnosis of active tuberculosis in people living with
HIV. The test is commercially available, does not require access to
special laboratory equipment, and produces a result after 25 min-
utes (Alere 2017), meeting many of the desired target product-pro-
file requirements (WHO TTP 2014).
The original Cochrane Review of LF-LAM for tuberculosis included
12 studies (Shah 2016). In that review, six studies evaluated accu-
racy among symptomatic individuals and found a low pooled sen-
sitivity of 45% (Credible Interval (CrI) 29% to 63%) and specificity of
92% (CrI 80% to 97%) against a microbiological reference standard
(Shah 2016). In participants with CD4 ≤ 100 cells/μL, pooled sensi-
tivity increased to 56% (CrI 41% to 70%) and specificity decreased
to 90% (81% to 95%). In the original review, the accuracy of LF-LAM
was also evaluated in participants not assessed of symptoms (i.e.
termed ‘TB screening’ and now described as studies among ‘unse-
lected participants’) with sensitivity ranging from 0% to 44% (Shah
2016).
In 2015, informed by the original Cochrane Review, the WHO made
a conditional recommendation for using LF-LAM to assist with the
diagnosis of tuberculosis in HIV-positive people with advanced dis-
ease (described below) and a strong recommendation against us-
ing the test “as a screening test for tuberculosis” based on the da-
ta among unselected participants (WHO Lipoarabinomannan Poli-
cy Guidance 2015).
Since 2015, additional evidence for the use and clinical impact of
LF-LAM has emerged. This Cochrane Review update includes pub-
lished studies evaluating the accuracy of the commercially avail-
able LF-LAM, Alere Determine TB LAM Ag assay for diagnosis of ac-
tive tuberculosis (pulmonary and extrapulmonary tuberculosis) in
people living with HIV and informed the updated WHO guidelines
on the use of the test. Of note, in 2018, preliminary performance
characteristics of a second commercially developed lateral flow as-
say to detect LAM for the diagnosis of tuberculosis was announced
based on data from frozen biobank specimens (Fujifilm SILVAMP TB
LAM, Japan; FujiLAM) (Broger 2019). The test is projected to become
commercially available in 2020; no studies of FujiLAM accuracy are
included in this updated review.
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Target condition being diagnosed
The target condition is active tuberculosis, which includes pul-
monary and extrapulmonary tuberculosis.
Index test(s)
The urine-based lateral flow lipoarabinomannan immunocapture
assay (LF-LAM) is a commercially available point-of-care test for ac-
tive tuberculosis (Alere Determine™ TB LAM Ag, Abbott, Palatine,
IL, USA, previous Alere Inc., Waltham, MA, USA). Lipoarabinoman-
nan (LAM) is a lipopolysaccharide present in mycobacterial cell
walls (Brennan 2003), which is released from metabolically active
or degenerating bacterial cells during tuberculosis disease (Briken
2004). LAM is detectable in urine of people with active tuberculo-
sis disease and evaluated for both LAM ELISA and the LF-LAM test-
ing platforms (Lawn 2012; Minion 2011; Peter 2010; Shah 2016).
The original Cochrane Review of LF-LAM (Shah 2016) and a meta-
analysis of an earlier generation LAM ELISA test (Minion 2011) both
demonstrated that the accuracy of urinary LAM detection was im-
proved among people living with HIV with advanced immunosup-
pression. Several hypotheses may explain the higher sensitivity of
urine LAM detection in people living with HIV including higher bacil-
lary burden and antigen load (Shah 2010), greater likelihood of gen-
itourinary tract tuberculosis involvement, and greater glomerular
permeability to allow increased antigen levels in urine (Lawn 2016;
Minion 2011).
LF-LAM testing is performed manually by applying 60 µL of un-
processed urine to the sample pad of the DetermineTB LAM Ag test
and leave the strip test to incubate at room temperature for 25 min-
utes (Alere 2017; Appendix 1). The strip is then inspected by eye. The
intensity of any visible band is graded by comparing it with the in-
tensities of the bands on a manufacturer-supplied reference scale
card. Of note, the reference scale was revised in January 2014. Prior
to January 2014, the reference scale card included five bands (grade
1 representing a very low intensity band to grade 5 representing a
high/dark intensity band). After January 2014, the manufacturer re-
vised the reference scale card to have four reference bands, such
that the band intensity for the new grade 1 corresponded to the
band intensity for the previous grade 2 (Appendix 2). Under the cur-
rent manufacturer recommendations (using the revised four bands
reference card), only bands that are grade 1 or higher are consid-
ered positive (Alere 2017; Appendix 2).
Clinical pathway
Based on current WHO guidelines (WHO Lipoarabinomannan Policy
Guidance 2015), the proposed role for the LF-LAM test is as an ‘add
on’ to clinical judgement and with other tests to assist in tubercu-
losis diagnosis. The test does not have a role as a replacement or
triage test. The reason for specifying ‘clinical judgement’ is that, in
our view, clinical judgement for HIV-associated tuberculosis carries
more importance than in many other cases (i.e. tuberculosis treat-
ment may be provided regardless of the test results). The reason
for specifying ‘add on’ is that for settings where the test is not avail-
able, the same clinical judgement is used; hence for settings where
the test is available, it is used ‘in addition’. Importantly, some HIV-
positive people may have difficulties in producing a good quality
sputum specimen or any sputum at all.
In the WHO policy guidance on the use of LAM, it is recommend-
ed that LF-LAM "may be used to assist in the diagnosis of tuber-
culosis in HIV-positive adult inpatients with signs and symptoms
of tuberculosis (pulmonary/and/or extrapulmonary) and a CD4 cell
count less than or equal to 100 cells/μL, or in people living with HIV
who are ‘seriously ill' regardless of CD4 count or if the CD4 count is
unknown" (WHO Lipoarabinomannan Policy Guidance 2015). The
recommendations also apply to HIV-positive outpatients and chil-
dren with signs and symptoms of tuberculosis (pulmonary and/or
extrapulmonary) based on the generalization of data from adult
inpatients while acknowledging the limitation of available data
(WHO Lipoarabinomannan Policy Guidance 2015). The WHO rec-
ommends that LF-LAM should not be used for general tuberculo-
sis screening "owing to suboptimal sensitivity" (WHO Lipoarabino-
mannan Policy Guidance 2015).
In 2016, WHO developed an algorithm for managing people living
with HIV presumed to have tuberculosis that was published as part
of the guidelines on use of ART for treating and preventing HIV infec-
tion (WHO ART Guidelines 2016). The algorithm recommends the
Xpert® MTB/RIF assay (Cepheid, Sunnyvale, USA) as the initial di-
agnostic test in adults and children with presumed HIV-associated
tuberculosis (WHO Xpert® Policy Update 2013). It is recommend-
ed that Xpert® MTB/RIF should be used rather than conventional
microscopy and culture for testing sputum and specific extra-pul-
monary specimens like cerebrospinal fluid and lymph nodes (WHO
Xpert® Policy Update 2013). The algorithm includes recommenda-
tions on use of LF-LAM as a test that may assist in diagnosing active
tuberculosis among seriously ill adults and children living with HIV,
regardless of CD4 count (WHO ART Guidelines 2016). Use of LF-LAM
is also included as one of the components in the package for diag-
nosis of tuberculosis in the WHO guidelines for managing people
presenting with advanced HIV (WHO Managing Advanced HIV Dis-
ease 2017).
When extrapulmonary tuberculosis is suspected, it is recommend-
ed to obtain "appropriate specimens from the suspected sites of
involvement for microscopy, culture, and histopathological exam-
ination" (TB CARE I 2014). A newly published Cochrane Review
found that Xpert MTB/RIF may be helpful in confirming the diagno-
sis of extrapulmonary tuberculosis (Kohli 2018). However, evalua-
tion for extrapulmonary tuberculosis often requires invasive diag-
nostic procedures that may have low yield even in people with ad-
vanced disease.
To identify those who need referral for tuberculosis diagnostic test-
ing, the WHO guidelines on intensified case-finding in people living
with HIV recommend that, in resource-constrained settings, peo-
ple living with HIV who report "any one of the symptoms of current
cough, fever, weight loss, or night sweats should be evaluated for
tuberculosis and other diseases" referred to as the WHO symptom
screening rule (Getahun 2011; WHO ICF 2011). People living with HIV
with tuberculosis may however not exhibit common symptoms of
tuberculosis disease. In some settings with high prevalence of tu-
berculosis, clinicians have therefore considered evaluating all pa-
tients presenting for care for tuberculosis without assessment or
consideration of specific signs or symptoms of tuberculosis.
In the context of LF-LAM being recommended in combination with
existing tuberculosis tests to increase early tuberculosis diagnosis
and treatment, the downstream consequences of LF-LAM testing
include the following.
• True-positive (TP): people would benefit from rapid non-site
specific diagnosis and early initiation of tuberculosis treatment.
Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
9
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• True-negative (TN): people would be spared unnecessary treat-
ment and would benefit from reassurance and pursuit of an al-
ternative diagnosis.• False-positive (FP): people would likely experience anxiety and
morbidity caused by additional testing, unnecessary treatment,
and possible adverse effects; possible stigma associated with a
tuberculosis diagnosis; and a FP result may halt further diagnos-
tic evaluation. However, as FP results increase (specificity de-
crease) as CD4 count decrease, the observed FP results may be
due to an inability of the sickest patients to produce a sputum
specimen and are TP results being misclassified as FP. Given the
high mortality in persons living with HIV, acting on all positive
LF-LAM results may balance the possibly adverse effects associ-
ated with unnecessary diagnosis and treatment.• False-negative (FN): people would experience increased risk of
morbidity and mortality and delayed treatment initiation; there
would be continuous risk of tuberculosis transmission. These
concerns may, however, be limited when using LF-LAM in com-
bination with existing tuberculosis tests.
Importantly, it should be noted that LF-LAM does not provide infor-
mation about drug resistance and some individuals with uniden-
tified drug-resistant tuberculosis may be inappropriately treated
with a regimen appropriate for drug-susceptible tuberculosis.
Alternative test(s)
In this section, we briefly describe selected alternative tests for de-
tection of tuberculosis. For a comprehensive review of these tests,
we refer the reader to several excellent resources (Lewinsohn 2017;
Unitaid 2017).
Smear microscopy (light microscopy (Ziehl-Neelsen), fluores-
cence microscopy, or light-emitting diode (LED) fluorescence mi-
croscopy) is the examination of smears for acid-fast bacilli (tuber-
culosis bacteria) under a microscope. Advantages of smear mi-
croscopy include its simplicity, low cost, speed, and high specificity
in high tuberculosis burden areas. In addition, smear microscopy
identifies the most infectious tuberculosis patients. Smear mi-
croscopy can be performed in basic laboratories. Drawbacks of
smear microscopy include the need for specialized training and its
relatively low sensitivity, 50% to 60% on average for a direct smear.
Among people living with HIV sensitivity is reported as low as 22%
to 43% (Getahun 2007). Around 5000 to 10,000 organisms per mL
must be present in the specimen for tuberculosis bacteria to be vis-
ible by microscopy (Lewinsohn 2017). Although, the sensitivity of
microscopy can be improved by approximately 10% with fluores-
cence (Steingart 2006), a large number of tuberculosis cases still
go undiagnosed if tuberculosis diagnosis solely relies on sputum
smear microscopy. Smear-negative tuberculosis is disproportion-
ately more common in HIV-positive than HIV-negative individuals,
accounting for 24% to 61% of all pulmonary cases in people living
with HIV, the yield decreasing with lower CD4 cell counts (Getahun
2007; Perkins 2007).
Mycobacterial culture is a method used to grow bacteria on nutri-
ent-rich media. In comparison with microscopy, a positive culture
requires only around 100 organisms per mL and therefore can de-
tect lower numbers of tuberculosis bacteria (Lewinsohn 2017). Ad-
ditionally, culture is essential for species identification and drug
susceptibility testing. However, culture may take up to six to eight
weeks and requires a highly equipped laboratory.
Nucleic acid amplification tests (NAATs) are molecular systems that
can detect small quantities of genetic material (DNA or RNA) from
microorganisms, such as M tuberculosis. The key advantage of
NAATs is that they are rapid diagnostic tests, potentially providing
results in a few hours. A variety of molecular amplification methods
are available, of which polymerase chain reaction (PCR) is the most
common. NAATs are available as commercial kits and in-house tests
(based on a protocol developed in a laboratory) and are used rou-
tinely in high-income countries for tuberculosis detection. In-house
PCR is widely used in low-income countries because these tests
are less expensive than commercial kits. However, in-house PCR is
known to produce highly inconsistent results (Flores 2005).
Xpert MTB/RIF and Xpert Ultra, the newest version (Cepheid, Sun-
nyvale, USA), are fully automated NAATs, that simultaneously
and rapidly detect M tuberculosis complex and rifampicin resis-
tance (WHO Xpert® Policy Update 2013; WHO Xpert Ultra 2017). A
Cochrane Review found that Xpert MTB/RIF was sensitive and spe-
cific for both pulmonary tuberculosis detection and rifampicin re-
sistance detection (Horne 2019). Compared with Xpert MTB/RIF,
Xpert Ultra had higher sensitivity and lower specificity for tuber-
culosis and similar sensitivity and specificity for rifampicin resis-
tance (one study) (Horne 2019). Although sputum testing with Xpert
MTB/RIF has high sensitivity for smear-positive pulmonary tuber-
culosis (98%), sensitivity is lower for smear-negative pulmonary tu-
berculosis (67%) (Horne 2019). In another Cochrane Review includ-
ing 66 studies evaluating Xpert MTB/RIF for detection of extrapul-
monary tuberculosis, pooled sensitivity was found to vary across
different types of specimens from 31% in pleural tissue to 97% in
bone or joint fluid, whereas specificity varied less from 82% in bone
or joint tissue to 99% in pleural fluid and urine (Kohli 2018). These
finding have bearing for HIV-associated tuberculosis where smear-
negative tuberculosis and extrapulmonary tuberculosis are dispro-
portionately higher. In 2017, based on a non-inferiority analysis of
Xpert Ultra compared with Xpert MTB/RIF, the WHO stated that rec-
ommendations on the use of Xpert MTB/RIF also apply to the use of
Xpert Ultra as the initial diagnostic test for all adults and children
with signs and symptoms of tuberculosis (WHO Xpert Ultra 2017).
The loop-mediated isothermal amplification test, TB-LAMP (Eiken
Chemical Co., Tokyo, Japan), has been recommended by the WHO
since 2016, for diagnosing pulmonary tuberculosis in adults (WHO
TB-LAMP 2016). It is a manual and simple assay that can be per-
formed directly on sputum samples with a result provided in less
than one hour (Yuan 2014). It is suitable for use at peripheral health
centres and is promoted as a test more sensitive than microscopy,
but inferior to Xpert MTB/RIF (WHO TB-LAMP 2016).
FujiLAM is a novel, lateral flow urine-based, point-of-care test for
tuberculosis diagnosis in people living with HIV in low-resource set-
tings. This assay was developed to detect LAM with results avail-
able in less than one hour and was announced on 26 September
2018, the day of the first United Nations General Assembly high-
level meeting on tuberculosis (FIND 2018). Fuji LAM has been eval-
uated on frozen biobank samples originating from various studies
of hospitalized HIV-positive patients with an estimated sensitivity
of 70% (Broger 2019). Studies are ongoing to evaluate FujiLAM per-
formance on bio-samples stored from outpatient HIV-cohorts and
prospective studies to evaluate the diagnostic accuracy of FujiLAM
are now called for as the next step forward. These trials are being
supported by the Global Health Innovative Technology fund and
the German Federal Ministry of Education and Research. The Foun-
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dation for Innovative New Diagnostics (FIND) participated in devel-
opment of the test, that was supported by the governments of the
Netherlands and Australia, UK aid from the UK government, and the
Bill & Melinda Gates Foundation.
Rationale
To address tuberculosis as the leading cause of morbidity and mor-
tality among people living with HIV, new tests and strategies for
detection of tuberculosis are urgently needed. Among the key pri-
orities identified by the WHO, healthcare providers, patients, and
advocacy groups is development of point-of-care, non-site specific
tests for tuberculosis (Batz 2011; Pai 2012; Weyer 2011; WHO TTP
2014). To date, LF-LAM is the only commercially available point-
of-care test for tuberculosis. LF-LAM, if sufficiently accurate, would
satisfy many of the established minimum specifications for a point-
of-care test for tuberculosis (Appendix 3; Batz 2011). LF-LAM test-
ing could provide obvious benefits for HIV-positive people by earli-
er detection of pulmonary tuberculosis that may be missed by spu-
tum smear microscopy and sputum Xpert MTB/RIF and extrapul-
monary tuberculosis that may be missed by sputum-based testing.
Studies that evaluate the impact of the use of LF-LAM on mortality
and other patient outcomes are becoming available.
WHO guidelines on the use of urine LF-LAM were published in
2015 (WHO Lipoarabinomannan Policy Guidance 2015). Since 2015,
additional evidence on the diagnostic accuracy of LF-LAM has
emerged and is summarized in this Cochrane Review update. A
draU of this review was used to inform the 2019 updated WHO
guidelines on the use of LF-LAM.
O B J E C T I V E S
Primary objectives
We had two primary objectives:
1. To assess the accuracy of the lateral flow urine lipoarabino-
mannan assay (LF-LAM) for the diagnosis of active tuberculosis
among HIV-positive adults with signs and symptoms of tubercu-
losis.
2. To assess the accuracy of LF-LAM for the diagnosis of active tu-
berculosis among HIV-positive adults irrespective of signs and
symptoms of tuberculosis (i.e. unselected participants without
consideration or assessment of tuberculosis signs and symp-
toms).
To estimate accuracy in HIV-positive individuals with signs and
symptoms of tuberculosis (Objective 1), we combined studies in
which presentation with signs and symptoms suggestive of tuber-
culosis was an inclusion criterion and refer to these as ‘Studies
with symptomatic participants’. To estimate accuracy in HIV-posi-
tive adults irrespective of signs and symptoms of tuberculosis (Ob-
jective 2), we combined studies that considered all HIV-positive in-
dividuals eligible to participate, including both individuals with and
individuals without symptoms of tuberculosis and refer to these as
‘Studies with unselected participants’. These studies enrolled par-
ticipants without assessment or consideration of specific signs or
symptoms of tuberculosis.
Secondary objectives
Our secondary objective was to investigate potential sources of
heterogeneity in test accuracy, including clinical setting, CD4 cell
count, and prevalence of tuberculosis in the studies.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included primary studies that evaluated the diagnostic accu-
racy of urine LF-LAM assay for the detection of active tuberculosis
in people living with HIV and compared the index test results with
a defined microbiological reference standard. We included studies
from which we could extract true positives (TP), false positives (FP),
true negatives (TN), and false negatives (FN) values.
Diagnostic studies for tuberculosis are largely cross-sectional in de-
sign, but may include some clinical follow-up as part of patient clas-
sification. We included cross-sectional studies and observational
cohort studies. In addition, we included randomized controlled tri-
als that evaluated the use of the index test on patient health out-
comes, but that also reported sensitivity and specificity. Although
the study design was a randomized trial for the purpose of deter-
mining the impact of the test on participant outcomes, the study
design was a cross-sectional study for the purpose of determining
the diagnostic accuracy of the index test in this review. We exclud-
ed case-control studies and other study designs. We excluded data
reported only in abstracts, reviews, comments, and editorial notes.
We did not include unpublished studies.
Participants
People living with HIV are at increased risk of tuberculosis and may
present with symptoms of tuberculosis but may also be asympto-
matic or have symptoms not routinely associated with tuberculo-
sis. We included participants who were adults (15 years and older is
considered ‘adult' for purpose of tuberculosis surveillance) and HIV
positive. We included studies in which there was a suspicion of tu-
berculosis among study participants based on the presence of signs
and symptoms compatible with tuberculosis (studies with symp-
tomatic participants), as well as studies that included participants
who presented for medical care irrespective of signs and symptoms
of tuberculosis (studies with unselected participants). Signs and
symptoms of tuberculosis include cough, fever, weight loss, and
night sweats. Participants who were known to have active tubercu-
losis and were taking anti-tuberculosis drugs were not included.
Index tests
We included studies that evaluated the lateral flow lipoarabino-
mannan (LF-LAM) assay Alere Determine™ TB LAM Ag test (Abbott,
Palatine, IL, USA, previous Alere Inc., Waltham, MA, USA) on urine
samples. As of May 2019, the Alere Determine™ TB LAM Ag test was
the only commercially available LF-LAM assay that had been eval-
uated in published studies.
We included studies that evaluated the test at the manufacturer's
recommended threshold for positivity, i.e. grade 1 and above on
the updated reference scale card with four band intensities graded
on a scale of 1 to 4. For studies that used the prior reference scale
card with band intensities graded on a scale of 1 to 5, we includ-
ed those that evaluated the test at grade 2 and above correspond-
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ing to the current recommended positivity threshold. We excluded
studies that did not use a positivity threshold corresponding to the
manufacturer's recommendations. Results summarizing diagnos-
tic accuracy at older thresholds (grade 1 on a scale of 1 to 5) can be
found in the original review (Shah 2016).
Target conditions
The target condition was active tuberculosis, which includes pul-
monary and extrapulmonary tuberculosis.
Reference standards
We required studies to diagnose tuberculosis using the following
microbiological reference standard.
• ‘Tuberculosis' is defined as a positive M tuberculosis culture or
NAAT.• ‘Not tuberculosis' is defined as a negative M tuberculosis culture
and NAAT (if performed).
NAAT tests included: Enhanced Amplified Mycobacterium Tuber-
culosis Direct Test (E-MTD, Gen-Probe, San Diego, USA); Amplicor
Mycobacterium tuberculosis Test (Amplicor, Roche Diagnostics,
Basel, Switzerland); COBAS® TaqMan® MTB Test (Roche Diagnos-
tics); GenoType MTBDRplus (HAIN Lifesciences, Nehren, Germany);
Xpert® MTB/RIF assay (Cepheid, Sunnyvale, USA); and Xpert® MTB/
RIF Ultra.
We considered a higher quality reference standard to be one in
which two or more specimen types were evaluated for tuberculo-
sis diagnosis in all participants as part of a standardized study algo-
rithm. We considered a lower quality reference standard to be one
in which only one specimen type was evaluated for tuberculosis di-
agnosis, or if there was no algorithm defined to ensure a standard-
ized approach for specimen collection and testing.
A microbiological reference standard, primarily culture, is consid-
ered the best reference standard. We expected all studies to obtain
sputum specimens and some studies to obtain additional speci-
mens for culture. However, the primary concern with relying on
sputum culture alone is that tuberculosis diagnosis may be missed
for the following reasons: people living with HIV may not be able
to provide sputum specimens of sufficient quality; sputum bacil-
lary load is typically low in people living with HIV; and a substantial
proportion of people with HIV-associated tuberculosis cannot pro-
duce sputum at all (Lawn 2013), or have extrapulmonary tuberculo-
sis without pulmonary tuberculosis. This means that index test TPs
may be misclassified as FPs by sputum culture. Therefore, when
evaluating LF-LAM with respect to sputum culture, the number of
FPs (classified as positive by the index test and negative by the ref-
erence test) may be increased and LF-LAM specificity may be un-
derestimated (Lawn 2015). This misclassification may also lead to
underestimation of sensitivity. Increasing the sensitivity of the ref-
erence standard by evaluating multiple specimens, including eval-
uating specimens from sites of disease for extrapulmonary tuber-
culosis, may reduce the number of cases of tuberculosis incorrectly
classified as ‘not tuberculosis' by culture or NAAT if performed.
In the original Cochrane Review, we additionally considered a
‘composite microbiological and clinical reference standard’ rec-
ognizing that microbiological reference standards alone may fail
to detect tuberculosis in patients with tuberculosis. However, our
original review found relatively little data using a composite refer-
ence standard; found heterogeneity in defining and applying com-
posite reference standards; and found a relatively modest impact
on pooled estimates of sensitivity and specificity comparing micro-
biological and composite reference standards. Results assessing
diagnostic accuracy against a composite reference standard can be
found in the original review (Shah 2016).
Given the limitations of the reference standard, we might have con-
sidered pursuing latent class analysis (Chu 2009; Kohli 2018). How-
ever, we lacked patient-level data on the type of specimen and LAM
is not site-specific, meaning a positive LAM alone does not tell us
whether the patient has pulmonary or extrapulmonary tuberculo-
sis.
Search methods for identification of studies
We attempted to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, and ongo-
ing). As mentioned, we only included published studies in this re-
view.
Electronic searches
We performed literature searches up to 11 May 2018 in the fol-
lowing databases using the search terms reported in Appen-
dix 4: the Cochrane Infectious Diseases Group Specialized Reg-
ister; MEDLINE (PubMed, from 1966); Embase (OVID, from 1947);
Science Citation Index Expanded (SCI-EXPANDED, from 1900), Con-
ference Proceedings Citation Index- Science (CPCI-S, from 1900),
and BIOSIS Previews (from 1926), all three using the Web of Science
platform; LILACS (BIREME, from 1982); and SCOPUS (from 1995).
We also searched Clinicaltrials.gov and the search portal of the
WHO International Clinical Trials Registry Platform (WHO ICTRP,
www.who.int/trialsearch) to identify ongoing trials, and ProQuest
Dissertations & Theses A&l (from 1861) to identify relevant disser-
tations. We included search results from the original review and re-
evaluated previously included studies to determine if the studies
met the refined inclusion criteria.
Searching other resources
We further examined reference lists of relevant reviews and studies
and searched the WHO websites.
Data collection and analysis
Selection of studies
We used Covidence systematic review software to manage the se-
lection of studies (Covidence 2017). Two review authors (MS and
SB) independently examined all titles and abstracts identified from
the electronic search to determine potentially eligible studies. We
obtained the full-text articles of these potentially eligible studies
and the same two review authors independently assessed inclusion
based on predefined inclusion and exclusion criteria. We resolved
disagreements through discussion and, if necessary, consulted a
third review author (KRS). We included studies from the original re-
view if still eligible according to the predefined eligibility criteria.
We maintained a list of excluded studies and the reasons for exclu-
sion, and recorded these details in the Characteristics of excluded
studies table and we prepared a PRISMA diagram.
Data extraction and management
We developed a standardized data extraction form and piloted the
form on two of the included studies. Based on the pilot, we final-
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ized the form (Appendix 5). Then two review authors (MS and SB)
independently extracted data from each included study on the fol-
lowing characteristics.
• Author, publication year, study design, country/countries, clini-
cal setting (outpatient or inpatient).• Participants: age, gender, HIV-status, CD4 count, tuberculosis
history, clinical status (asymptomatic, symptomatic).• Quality Assessment of Diagnostic Accuracy Studies-2
(QUADAS-2) items.• Cut-oS used for determining a positive index test result and the
reference card used.• Samples collected (sputum and/or extrapulmonary samples).• Reference standard(s).• The number of tuberculosis cases in the study.• Number of TP, FN, FP, and TN values.• Missing or unavailable test results.
We assigned country income status (high income, upper- and low-
er-middle income, and low income) as classified by the World Bank
(World Bank 2018). In addition, we classified a country as being high
burden or not high burden for tuberculosis/HIV according to the
post-2015 era classification by the WHO (WHO Global Tuberculosis
Report 2018). For studies that included both participants with HIV
and without HIV infection, we extracted data only for participants
with HIV. We contacted study authors for clarifications on the LF-
LAM positivity threshold used if data were missing.
We used REDCap electronic data capture tools (Harris 2009) host-
ed at OPEN, Odense Patient data Explorative Network, Odense Uni-
versity Hospital, Odense, Denmark (SDU Open) to collect and man-
age study data. REDCap (Research Electronic Data Capture) is a se-
cure, web-based application designed to support data capture for
research studies, providing: 1) an intuitive interface for validated
data entry; 2) audit trails for tracking data manipulation and export
procedures; 3) automated export procedures for seamless down-
loads to common statistical packages; and 4) procedures for im-
porting data from external sources. With regard to the use of RED-
Cap, the content in this review is solely the responsibility of the au-
thors.
Assessment of methodological quality
We used the QUADAS-2 tool tailored to this review to assess
the quality of the included studies (Whiting 2011; Appendix 6).
QUADAS-2 consists of four domains: patient selection, index test,
reference standard, and flow and timing (flow and timing domain
includes differential verification of tuberculosis status for study
participants). We assessed all domains for risk of bias and the
first three domains for concerns regarding applicability. As recom-
mended, we first developed the guidance on how to appraise the
questions in each domain. Then, one review author (SB) piloted the
tool with two of the included studies and finalized the QUADAS-2
tool. Two review authors (MS and SB) independently completed the
QUADAS-2 assessment. We resolved disagreements through dis-
cussion or consulted a third review author (KRS). We present the
results of this quality assessment in the text, tables, and graphs.
Statistical analysis and data synthesis
We performed descriptive analyses of the characteristics of the in-
cluded studies using Stata 15 (StataCorp 2017), and presented key
study characteristics in the ‘Characteristics of included studies' ta-
ble. We used the number of TPs, FPs, FNs, and TNs to calculate the
individual study estimates of sensitivity and specificity and their
95% confidence intervals (CIs). We presented individual study re-
sults graphically by plotting the estimates of sensitivity and speci-
ficity (and their 95% CIs) in forest plots using Review Manager 5
(RevMan 5) (Review Manager 2014).
We presented results at the current manufacturer reference scale
card for test interpretation, with band intensities graded 1 to 4, and
considered all test results at grade 1 and above as positive. The
prior reference scale card with five band intensities was used in
the original Cochrane Review with grade 2 considered as positivity
threshold that corresponds to the current grade 1 band intensity
(Appendix 2). The original review also included several analyses at
grade 1 which is no longer recommended for determining test pos-
itivity. To allow consistent comparisons, we converted results from
older studies that used the ‘grade 2’ threshold and treated these as
‘grade 1’ in the updated review. As such, analyses labelled at ‘grade
2’ in the original Cochrane Review are in this review considered ac-
cording to the new manufacturer reference card as ‘grade 1’. Stud-
ies in the original review that used the ‘grade 1’ threshold on the
prior reference card were not included as this threshold is no longer
recommended for determining test positivity.
We grouped the studies evaluating LF-LAM for: (I) diagnosis of tu-
berculosis in HIV-positive people with signs and symptoms of tu-
berculosis i.e. ‘Studies with symptomatic participants' and (II) di-
agnosis of tuberculosis in HIV-positive people, irrespective of signs
and symptoms of tuberculosis i.e. ‘Studies with unselected partic-
ipants'.
When data were sufficient, we carried out meta-analyses to esti-
mate LF-LAM pooled sensitivity and specificity with a bivariate ran-
dom-effects model (Chu 2006; Reitsma 2005). This approach al-
lowed us to calculate pooled sensitivity and specificity while deal-
ing with potential sources of variation caused by: (1) imprecision
of sensitivity and specificity estimates within individual studies; (2)
correlation between sensitivity and specificity across studies; and
(3) variation in sensitivity and specificity between studies.
We estimated all models using a Bayesian approach implement-
ed using OpenBUGS (Lunn 2009). Under the Bayesian approach,
all unknown parameters must be provided a prior distribution that
defines the range of possible values of the parameter and the
weight of each of those values, based on information external to the
data. Because most meta-analyses involved few studies (eight or
less), which could lead the model to be just identified, we chose to
use low-information prior distributions for most parameters and a
more informative prior on the between-study standard deviations
which are particularly sensible in meta-analyses with few studies
(Spiegelhalter 2004).
We defined prior distributions on the log-odds scale over the
pooled sensitivity and specificity parameters, their correspond-
ing between-study standard deviations (SDs) and the correlation
between the sensitivities and specificities across studies. For the
pooled log odds of the sensitivity or log odds of the specificity, we
used a normal prior distribution with mean 0 and a variance of 4
(or a precision of 0.25). This corresponds to a roughly uniform dis-
tribution over the pooled sensitivity and pooled specificity on the
probability scale. The 2.5% and 97.5% prior distribution quantiles
for the pooled sensitivity or pooled specificity are 2.0% and 98.0%,
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slightly wider than for a standard normal distribution. For the be-
tween-study precision we used a gamma distribution with a shape
parameter of two and rate parameter of 0.5. This corresponds to
a 95% prior credible interval (CrI) for the between-study SD in the
log odds of sensitivity or log odds of specificity ranging from rough-
ly 0.29 to 1.44, corresponding to moderate to high values of be-
tween-study heterogeneity. The resulting median 2.5% and 97.5%
prior distribution quantiles for the predicted sensitivity or predict-
ed specificity are 0.1% and 99.9%. Covariance terms followed a uni-
form prior distribution whose upper and lower limits were deter-
mined by the sensitivity of the two tests. We have summarized the
models we used (including the prior distributions) and the Open-
BUGS programs we used to estimate them in Appendix 7.
To study the sensitivity of our results to the choice of prior distri-
butions given above, we considered alternative prior distributions
that were less informative, which allowed a wider range of possible
values. We increased the variance of the normal distributions over
the pooled log odds of the sensitivity or specificity to 100. We used
a uniform prior distribution ranging from zero to three over the be-
tween-study SD on the log odds scale. We found that the pooled es-
timates remained roughly the same with these alternative priors,
though the posterior CrIs were wider, as expected. We combined in-
formation from the prior distribution with the likelihood of the ob-
served data, in accordance with Bayes’ theorem in the OpenBUGS
program, which resulted in a sample from the posterior distribu-
tion of each unknown parameter. Using this sample, we calculat-
ed various descriptive statistics of interest. We estimated the medi-
an pooled sensitivity and specificity and their 95% CrI. The median
or the 50% quantile is the value below which 50% of the posterior
sample lies. We reported the median because the posterior distrib-
utions of some parameters may be skewed, and the median would
be considered a better point estimate of the unknown parameter
than the mean in such cases. The 95% CrI is the Bayesian equivalent
of the classical (frequentist) 95% confidence interval (CI) (we indi-
cated 95% CI for individual study estimates and 95% CrI for pooled
study estimates as appropriate). The 95% CrI may be interpreted as
an interval that has a 95% probability of capturing the true value
of the unknown parameter given the observed data and the prior
information.
We also estimated the predicted sensitivity and specificity in a fu-
ture study together with their 95% CrIs. The predicted estimate is
our best guess for the estimate in a future study and is the same
as the pooled estimate. The CrIs, however, may be different. These
values were derived from the predicted region typically reported
in a bivariate meta-analysis plot. If there is no heterogeneity be-
tween the included studies, the CrI around the predicted estimate
will be the same as the CrI around the pooled estimate. On the oth-
er hand, if there is considerable heterogeneity between studies, the
CrI around the predicted estimate will be much wider than the CrI
around the pooled estimate. We generated summary plots display-
ing the individual study estimates for sensitivity and specificity, the
pooled estimate for sensitivity and specificity with the 95% credi-
ble region and the 95% prediction region using R (R Statistical Com-
puting 2018).
In our original review we evaluated the incremental change in
sensitivity and specificity when combining LF-LAM with smear mi-
croscopy or Xpert MTB/RIF (Shah 2016). We did not undertake
analysis of incremental benefit in the current review as it was be-
yond the scope of this review, and data within published manu-
scripts were limited.
Approach to uninterpretable LF-LAM results
We excluded uninterpretable test results from the meta-analyses of
sensitivity and specificity, but we reported the number and propor-
tion of uninterpretable test results from each study when such data
were available.
Investigations of heterogeneity
Initially, we investigated heterogeneity through visual examination
of forest plots of sensitivities and specificities and through visual
examination of the ROC plot of the raw data. When data were suffi-
cient, we performed subgroup analyses with the following categor-
ical covariates: clinical setting (inpatient versus outpatient); CD4
count (CD4 ≤ 200; CD4 ≤ 100; CD4 101-200; CD4 > 200 and; CD4 > 100
cells per µL). To further investigate heterogeneity, we performed
a subgroup analysis by the prevalence of tuberculosis in the stud-
ies and classified prevalence as greater than the median value ver-
sus less than or equal to the median value. We investigated hetero-
geneity separately for studies with symptomatic participants and
studies with unselected participants. We generated the plots de-
picting the pooled results within CD4 count categories using R (R
Statistical Computing 2018).
Sensitivity analyses
We performed sensitivity analyses by limiting inclusion in the meta-
analysis to the following.
• Studies that avoided inappropriate exclusions, for example,
studies that included participants who could not produce spu-
tum. For this analysis we included studies that we scored as ‘yes'
for the QUADAS-2 question, "Did the study avoid inappropriate
exclusions?" (low risk of bias for participant selection).• Studies with a higher quality reference standard, for example
studies that included two or more specimen types. For this
analysis, we included studies that we scored as ‘yes’ for the
QUADAS-2 question, “Is the reference standard likely to correct-
ly classify the target condition?” (low risk of bias for the refer-
ence standard).• Studies that used only fresh urine specimens for LAM testing.• Studies initially categorized as ‘studies among unselected par-
ticipants’ that included more than 80% of symptomatic partici-
pants were re-categorized as ‘studies with symptomatic partici-
pants’. We conducted this analysis to explore the possibility that
these studies represented a comparable population to the stud-
ies of symptomatic participants even though participants were
not explicitly enrolled in the study on the basis of specific tuber-
culosis symptoms.
Assessment of reporting bias
We did not carry out a formal assessment of publication bias using
methods such as funnel plots or regression tests because such tech-
niques have not been helpful for diagnostic test accuracy studies
(Macaskill 2010).
Assessment of the certainty of the evidence
We assessed the certainty of evidence as recommended using the
GRADE approach (Balshem 2011; Schünemann 2008; Schünemann
2016). As recommended, we rated the certainty of evidence as ei-
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ther high (not downgraded), moderate (downgraded by one lev-
el), low (downgraded by two levels), or very low (downgraded by
more than two levels) based on five domains: risk of bias, indirect-
ness, inconsistency, imprecision, and publication bias. For each
outcome, the certainty of evidence started as high when there were
high-quality observational studies (cross-sectional or cohort stud-
ies) that enrolled participants with diagnostic uncertainty. If we
found a reason for downgrading, we used our judgement to classify
the reason as either serious (downgraded by one level) or very se-
rious (downgraded by two levels).
Four review authors (SB, MS, ND, and KRS) discussed judgments
and applied GRADE in the following way.
• Risk of bias: we used QUADAS-2 to assess risk of bias.• Indirectness: we used QUADAS-2 for concerns of applicability
and looked for important differences between the populations
studied (for example, in the spectrum of disease), the setting,
and index test and asked are differences sufficient to lower cer-
tainty in results?• Inconsistency: GRADE recommends downgrading for unex-
plained inconsistency in sensitivity and specificity estimates.
We carried out pre-specified analyses to investigate potential
sources of heterogeneity and did not downgrade when we felt
we could explain inconsistency in the accuracy estimates.• Imprecision: we considered a precise estimate to be one that
would allow a clinically meaningful decision. We considered the
width of the CrI, and asked ourselves, “Would we make a differ-
ent decision if the lower or upper boundary of the CrI represent-
ed the truth?” In addition, we worked out projected ranges for
TP, FN, TN, and FP for a given prevalence of tuberculosis and
made judgements on imprecision from these calculations.• Publication bias: we rated publication bias as undetected (not
serious) for several reasons including the comprehensiveness of
the literature search and extensive outreach to tuberculosis re-
searchers to identify studies.
R E S U L T S
Results of the search
We identified 15 unique studies that met the inclusion criteria
of this review. We included data from six published manuscripts
from the original WHO Guidelines (WHO Lipoarabinomannan Policy
Guidance 2015), and Cochrane Review (Shah 2016) that met the re-
fined inclusion criteria (Bjerrum 2015; Drain 2015a; LaCourse 2016;
Nakiyingi 2014; Peter 2012a; Peter 2015), and nine new studies
identified in the updated search (Drain 2016; Floridia 2017; Hanifa
2016; Huerga 2017; Juma 2017; Lawn 2017; Pandie 2016; Peter 2016;
Thit 2017). Of six previously included studies, three were exclud-
ed because they did not use the currently recommended thresh-
old for test positivity (Balcha 2014; Drain 2014a; Lawn 2012a); one
previously included abstract (Lawn 2014) was added as an updated
published manuscript (Lawn 2017); one abstract remained unpub-
lished (Andrews 2014); and one abstract was published but did not
provide diagnostic accuracy data (Drain 2014b). Eight studies eval-
uated the accuracy of LF-LAM for tuberculosis diagnosis in partici-
pants with signs and symptoms suggestive of tuberculosis. Seven
studies evaluated the accuracy of LF-LAM for diagnosis of unselect-
ed participants without assessment of symptoms (i.e. patients may
or may not have had tuberculosis signs and symptoms at enrol-
ment).
Figure 1 shows the flow of studies in the review. We listed the ex-
cluded studies and the reasons for their exclusion in the ‘Character-
istics of excluded studies' section. All studies were written in Eng-
lish.
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Figure 1.   Study flow diagram
 
Methodological quality of included studies
Risk of bias and applicability concerns for each of the 15 included
studies is shown in Figure 2; Figure 3.
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Figure 2.   Studies with symptomatic participants - Risk of bias and applicability concerns summary: review authors'
judgements about each domain for each included study.
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Figure 3.   Studies with unselected participants - Risk of bias and applicability concerns summary: review authors'
judgements about each domain for each included study.
 
Studies with symptomatic participants
Eight studies were included that evaluated LF-LAM for tuberculo-
sis diagnosis among symptomatic participants suspected of tuber-
culosis. Risk of bias and applicability concerns for the studies with
symptomatic participants are shown in Figure 2.
In the patient selection domain, we considered six studies (75%) to
be at high risk of bias because: (1) the study excluded all smear-pos-
itive participants (Drain 2016); (2) the studies excluded participants
who could not expectorate or produce sputum despite sputum in-
duction (Drain 2016; Nakiyingi 2014; Peter 2015); (3) the study ex-
cluded participants from analysis if, in the absence of a positive ref-
erence standard result, there was one sample with no Xpert MTB/
RIF result or contaminated result (culture) (Huerga 2017); (4) the
study only included patients suspected of extrapulmonary tuber-
culosis and excluded patients suspected of pulmonary tuberculosis
(Juma 2017); (5) the study only included participants with pericar-
dial effusion and suspected tuberculosis and excluded participants
suspected of other forms of tuberculosis (Pandie 2016). All studies
were cross-sectional, cohort or randomized controlled studies. Re-
garding applicability, seven studies (88%) had low concern in the
patient selection domain because the studies included the appro-
priate participants and settings. We judged one study (12%) to have
high concern for applicability as the participants did not resem-
ble people with presumed HIV/tuberculosis co-infection i.e. partic-
ipants were smear-negative HIV-positive and HIV-negative patients
with a Karnofsky Performance score < 50 (Drain 2016).
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In the index test domain, we judged one study (12%) at high risk of
bias as the study used grade 2 (on the updated reference scale card)
as the test positivity threshold, as opposed to the current manufac-
turer recommendation to use grade 1 to define test positivity (Juma
2017). We also considered this study to have high concern of applic-
ability because the test procedure was inconsistent with the man-
ufacturers' recommendations (Juma 2017). The remaining studies
all used the recommended threshold for positivity and interpreted
the test without knowledge of the results of the reference standard,
and we considered them to have low concern for applicability.
In the reference standard domain, we considered seven studies
(88%) to be at high risk of bias because: (1) the studies did not in-
clude testing of any extrapulmonary specimens (Drain 2016, Peter
2015); (2) the study did not include testing of any respiratory sam-
ples (Juma 2017); (3) the study only tested respiratory samples for
some of the participants (Pandie 2016); (4) the study only tested
extrapulmonary specimens in addition to respiratory samples for
some of the participants (Huerga 2017); (5) health providers select-
ed the sites for testing based on their own clinical suspicion (Pe-
ter 2012a; Peter 2016). We deemed three studies at high concern
for applicability as they lacked a study or protocol directed test-
ing (Pandie 2016; Peter 2012a; Peter 2016). In these studies, health
providers selected the sites for testing based on their own clinical
suspicion, and it was unclear if their choice of reference standard
would correctly classify tuberculosis.
In the flow and timing domain, we considered four studies (50%)
to be at high risk of bias because not all participants received the
same reference standard (Huerga 2017; Peter 2012a; Peter 2016),
or because not all participants were included in the two-by-two ta-
bles ( Huerga 2017; Pandie 2016). We judged the remaining studies
to be at low risk of bias because all participants received the index
test, the same reference standard and no participants were exclud-
ed from the two-by-two table.
Studies with unselected participants
Seven studies contributed data for the purpose of evaluating LF-
LAM for tuberculosis diagnosis among unselected participants who
may or may not have tuberculosis signs or symptoms. Risk of bias
and applicability concerns for the studies with symptomatic partic-
ipants are shown in Figure 3.
In the patient selection domain, we considered four studies (57%)
to be at high risk of bias because these studies excluded partici-
pants who could not expectorate or produce sputum samples (Bjer-
rum 2015; Drain 2015a; Floridia 2017; LaCourse 2016). All studies
were cross-sectional or cohort studies. Regarding applicability, we
judged that all studies (100%) included the appropriate partici-
pants and settings.
In the index test domain, we considered all studies at low risk of bias
as all studies used LF-LAM, pre-specified the grade used for positiv-
ity, and interpreted the test at the recommended positivity thresh-
old without knowledge of the results of the reference standard. We
considered the test conduct and interpretation in all studies to be
applicable.
In the reference standard domain, we considered five studies (71%)
to be at high risk of bias because these studies did not include mi-
crobiological testing on extrapulmonary specimens (Bjerrum 2015;
Drain 2015a; Floridia 2017; LaCourse 2016; Thit 2017). Thit 2017
also did not report if the reference standard results were inter-
preted without knowledge of the index test result. One study (Thit
2017) did not report if they speciated mycobacteria isolates and
was judged to have unclear concern for applicability. We judged the
remaining six studies to be of low concern in terms of applicability.
In the flow and timing domain, we considered two studies (29%)
to be at high risk of bias because the studies collected specimens
for index and reference standard tests up to six months apart (Han-
ifa 2016; Thit 2017), and Hanifa 2016 excluded clinical tuberculo-
sis cases from analysis. We considered the remaining five studies
(71%) to be at low risk of bias because all participants received the
index test and the same reference standard, and no participants en-
rolled were excluded from the two-by-two table.
Findings
The 15 included studies involved 6814 participants, 1761 (26%)
with tuberculosis. Eight studies evaluated the accuracy of LF-LAM
for tuberculosis diagnosis in participants with signs and symptoms
suggestive of tuberculosis involving 3449 participants, 1277 (37%)
with tuberculosis. Seven studies evaluated the accuracy of LF-LAM
for diagnosis of unselected participants that may or may not have
had tuberculosis signs and symptoms at enrolment involving 3365
participants, 432 (13%) with tuberculosis.
All studies were performed in countries with a high tuberculo-
sis/HIV burden (WHO Global Tuberculosis Report 2018), and classi-
fied as low-income or middle-income countries (World Bank 2018).
We noted substantial differences in the studies for the following
characteristics: type of population (‘studies with symptomatic par-
ticipants' and ‘studies with unselected participants'); setting (in-
patients versus outpatients); median CD4 cell count; tuberculo-
sis prevalence; inclusion and exclusion of participants based on
whether or not they could produce sputa; and whether patients
were evaluated for pulmonary tuberculosis, extrapulmonary tuber-
culosis, or both. The key study characteristics are summarized in
Table 1 (Summary characteristics of included studies) and in Char-
acteristics of included studies.
Table 2 presents pooled sensitivity and specificity results for LF-
LAM grouped by the type of population, ‘studies among sympto-
matic participants' and ‘studies among unselected participants’.
I. Diagnostic accuracy of LF-LAM for tuberculosis diagnosis in
HIV-positive adults with signs and symptoms of tuberculosis
Of the 15 included studies, eight evaluated the accuracy of LF-
LAM for tuberculosis diagnosis in participants with signs and symp-
toms suggestive of tuberculosis (Drain 2016; Huerga 2017; Juma
2017; Nakiyingi 2014; Pandie 2016; Peter 2012a; Peter 2015; Peter
2016). The suggestive signs and symptoms of tuberculosis varied
from study to study, as described in Table 1 and in Characteristics
of included studies, but were often based on any of cough, fever,
weight loss, or night sweats as per the WHO symptom screening
rule WHO ICF 2011. The tuberculosis prevalence in the study pop-
ulation ranged from 29% to 63%. Two studies were conducted ex-
clusively among patients with presumed extrapulmonary tubercu-
losis (Juma 2017; Pandie 2016). Four studies were conducted exclu-
sively in an inpatient setting (Juma 2017; Pandie 2016; Peter 2012a;
Peter 2016); two studies exclusively in an outpatient setting (Drain
2016; Peter 2015); and two studies in both inpatient and outpatient
settings (Huerga 2017; Nakiyingi 2014). The median CD4 cell count
ranged from 81 to 210 cells per µL across the eight studies, lower in
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studies evaluating inpatients (median CD4 between 81 to 139 cells
per µL) compared to studies evaluating outpatients (median CD4
was 168 to 210 cells per µL). See Table 1 and Characteristics of in-
cluded studies.
Primary analysis, LF-LAM for tuberculosis in HIV-positive adults
with signs and symptoms of tuberculosis
For determining the overall accuracy of LF-LAM in HIV-positive
adults with signs and symptoms of tuberculosis, eight studies pro-
vided data for 3449 participants, including 1277 (37%) with tuber-
culosis. Sensitivity estimates ranged from 23% to 68%, and speci-
ficity estimates from 75% to 100% (Figure 4).
 
Figure 4.   Forest plots of LF-LAM sensitivity and specificity for tuberculosis against a microbiological reference
standard for studies among symptomatic participants. The individual studies are ordered by decreasing sensitivity.
TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. Between brackets are the 95%
confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of
the study (blue square) and its 95% CI (black horizontal line).
 
Juma 2017 evaluated diagnostic accuracy for extrapulmonary tu-
berculosis (all forms) exclusively and had the highest sensitivity of
68%. Pandie 2016 evaluated accuracy for pericardial tuberculosis
and found sensitivity of 33%. Sensitivity was lowest in the studies
by Peter 2015 and Drain 2016 that both reported a sensitivity of
23%. Differences between these studies and the other studies in
this analysis were the setting (outpatient only), focus on pulmonary
tuberculosis (no extrapulmonary samples were taken), and exclu-
sion of participants unable to produce sputum. In particular, Drain
2016 included smear-negative participants with presumed tuber-
culosis and a small number of HIV-negative participants. Drain 2016
further excluded participants with a low Karnofsky score in order
to target relatively well outpatients, where smear-negative tuber-
culosis is often seen. Specificity was lowest for Peter 2012a a study
that included only inpatients and differed from other studies in
that both sputum and non-sputum-based sampling was performed
at the discretion of the attending clinical team and not study di-
rected. Pandie 2016 reported the highest specificity of 100%. This
study, as mentioned, differed from others by evaluating accuracy
only for pericardial tuberculosis. The authors further excluded a
number of participants in the analysis for unknown reasons and re-
ported two true negatives and zero false positives that may have in-
flated specificity. The pooled sensitivity and specificity (95% cred-
ible interval (CrI)) were 42% (31% to 55%) and 91% (85% to 95%)
(Table 2). Appendix 8 presents the pooled and predicted sensitivi-
ty and specificity estimates together with the credible and predic-
tion regions for LF-LAM for tuberculosis detection. Prediction in-
tervals were very wide in all meta-analysis models indicating be-
tween-study heterogeneity (data not shown).
Uninterpretable index test results
Studies reported few uninterpretable test results. Peter 2012a re-
ported that 1% to 2% of 423 tests remained ‘indeterminate' (de-
fined as a broken band in the patient window) after repeat testing.
Peter 2016 reported that 0.3% (3/1172) test results remained ‘in-
valid' after a repeat test (defined as no control band identified in
the patient window or a broken/ incomplete band in the patient
window). Peter 2015 reported that fewer than 1% of LF-LAM strip
tests failed on the first attempt and required a second strip to pro-
duce valid results. Four studies reported that a valid LF-LAM result
was obtained on the first attempt for all tests (Drain 2016; Huerga
2017; Juma 2017; Nakiyingi 2014), and one study did not provide
information on uninterpretable tests (Pandie 2016).
Investigations of heterogeneity
LF-LAM accuracy among symptomatic participants, stratified by
setting
LF-LAM accuracy in inpatient settings
Six studies were conducted among inpatients involving 2253 par-
ticipants, 868 (39%) with tuberculosis (Huerga 2017; Juma 2017;
Nakiyingi 2014; Pandie 2016; Peter 2012a; Peter 2016). Sensitivity
estimates ranged from 33% to 69% and specificity estimates ranged
from 75% to 100% (Figure 5). The highest sensitivity (69%) was re-
ported by Huerga 2017 with a relatively low specificity (78%). This
study enrolled inpatients with tuberculosis symptoms who had at
least one of the following features: who were severely ill or who
had CD4 < 200 cell per µL (median CD4 109) or who had a low body
mass index (BMI). The study did not include microbiological or his-
tological evaluation of extrapulmonary specimens for tuberculosis
in their reference standard, which may have led to LAM-positive
participants with extrapulmonary tuberculosis being misclassified
as ‘false-positive’ and lowered specificity. Pandie 2016 reported the
lowest sensitivity (33%) and a specificity of 100%. As mentioned,
this study evaluated accuracy for pericardial tuberculosis and ex-
cluded participants from specificity analysis that may have affect-
ed the specificity estimate. The pooled sensitivity and specificity
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(95% CrI) among inpatients were 52% (40% to 64%) and 87% (78%
to 93%) (Table 2).
 
Figure 5.   Forest plots of LF-LAM sensitivity and specificity for tuberculosis against a microbiological reference
standard for studies among symptomatic participants, by health care setting. TP = True Positive; FP = False
Positive; FN = False Negative; TN = True Negative. The individual studies are ordered by decreasing sensitivity.
Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated
sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).
 
LF-LAM accuracy in outpatient settings
Four studies were conducted among outpatients involving 1196
participants, 409 (34%) with tuberculosis (Drain 2016; Huerga 2017;
Nakiyingi 2014; Peter 2015). Sensitivity estimates ranged from 18%
to 58% and specificity estimates ranged from 93% to 99% (Figure 5).
The highest sensitivity (58%) was reported by Huerga 2017 where
outpatients included were severely ill, or had a CD4 < 200 cell per
µL, or had a low BMI below 17 kg/m2. Among outpatients, pooled
sensitivity and specificity were 29% (17% to 47%) and 96% (91% to
99%) (Table 2).
LF-LAM accuracy among symptomatic participants, stratified by CD4
count
We included five studies in the analyses by CD4 count (Nakiyingi
2014; Peter 2012a; Peter 2015; Peter 2016). See Figure 6 and Figure
7.
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Figure 6.   Forest plots of LF-LAM sensitivity and specificity for tuberculosis against a microbiological reference
standard for studies with symptomatic participants, stratified by CD4 (CD4 > 200 and CD4 ≤ 200; CD4 > 100 and CD4 ≤
100). The individual studies are ordered by decreasing sensitivity. TP = True Positive; FP = False Positive; FN = False
Negative; TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity.
The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal
line).
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Figure 7.   Plot by CD4 of diagnostic accuracy in adults with signs and symptoms of tuberculosis. (A) Sensitivity
by CD4 strata; (B) Specificity by CD4 strata. The circle represents the pooled estimates (median), with bars
representing 95% credible intervals.
 
LF-LAM accuracy stratified by CD4 > 200 cells per µL and ≤ 200 cells per
µL
Three studies evaluated LF-LAM in participants with CD4 > 200 cells
per µL (Nakiyingi 2014; Peter 2012a; Peter 2016). Sensitivity esti-
mates ranged from 9% to 27% and specificity estimates ranged
from 83% to 99% (Figure 6). In the four studies that evaluated par-
ticipants with CD4 ≤ 200 cells per µL, sensitivity estimates ranged
from 24% to 58% and specificity estimates ranged from 72% to
95% (Nakiyingi 2014; Peter 2012a; Peter 2015; Peter 2016), (Figure
6). The pooled sensitivity (95% CrI) was higher among participants
with CD4 ≤ 200 cells per µL at 45% (31% to 61%) (4 studies, 1825 par-
ticipants, 40% with tuberculosis) versus 16% (8% to 31%) among
those with CD4 > 200 cells per µL (3 studies, 738 participants, 22%
with tuberculosis) (Table 2); a significant difference in pooled sen-
sitivity (95% CrI) of -29% (-47% to -9%). The pooled specificity was
89% (77% to 94%) for participants with CD4 ≤ 200 cells per µL and
94% (81% to 97%) for those with CD4 > 200 cells per µL (Table 2), a
difference in pooled specificity of 5% (-8% to 17%).
When we limited the analysis to studies involving inpatients with
CD4 ≤ 200 cells per µL, the pooled sensitivity and specificity were
54% (34% to 73%) and 80% (58% to 91%) (2 studies, 1009 partici-
pants, 34% with tuberculosis) (Peter 2012a; Peter 2016). Only one
study reported data for outpatients with CD4 ≤ 200 cells per µL (Pe-
ter 2015).
LF-LAM accuracy stratified by CD4 > 100 cells per µL and ≤ 100 cells per
µL
Four studies evaluated LF-LAM in participants with CD4 > 100 cells
per µL (Nakiyingi 2014; Pandie 2016; Peter 2015; Peter 2016). Sensi-
tivity estimates ranged from 12% to 19% and specificity estimates
ranged from 92% to 100% (Figure 6). In the five studies that evalu-
ated participants with CD4 ≤ 100 cells per µL, sensitivity estimates
ranged from 30% to 65% and specificity estimates ranged from 75%
to 94% (Nakiyingi 2014; Pandie 2016; Peter 2012a; Peter 2015; Pe-
ter 2016). One study had no estimable specificity, as the authors
reported zero true negatives (Pandie 2016). The pooled sensitivity
(95% CrI) was higher among participants with CD4 ≤ 100 cells per
µL at 54% (38% to 69%) (4 studies, 1239 participants, 41% with tu-
berculosis) versus 17% (10% to 27%), (4 studies, 1519 participants,
28% with tuberculosis) among those with CD4 > 100 cells per µL, a
significant difference in pooled sensitivity of -37% (-53% to -19%).
The pooled specificity was 88% (77% to 94%) for participants with
CD4 ≤ 100 cells per µL and 95% (89% to 98%) for those with CD4 >
100 cells per µL (Table 2), a difference in pooled specificity of 7%
(-1% to 18%).
When we limited the analysis to studies involving inpatients with
CD4 ≤ 100 cells per µL (Peter 2012a; Peter 2016), the pooled sensi-
tivity and specificity were 61% (40% to 78%) and 81% (61% to 91%).
Only one study reported data for outpatients with CD4 ≤ 100 cells
per µL (Peter 2015).
LF-LAM accuracy stratified by CD4 strata
We observed that LF-LAM pooled sensitivity increased as the de-
gree of immunodeficiency increased, from 16% (8% to 31%) in pa-
tients with CD4 cell count >200 cells per μL; to 24% (14% to 38%) in
patients with CD4 count between 101 to 199; to 54% (38% to 69%)
in patients with CD4 ≤ 100 (Figure 7). Also, we observed that most
participants contributing data for the CD4 ≤ 200 cells per µL stra-
tum (1825 participants including 722 (40%) with tuberculosis) were
participants with CD4 ≤ 100 cells per µL (1239 participants includ-
ing 512 (41%) with tuberculosis) (Table 2).
LF-LAM accuracy among symptomatic participants, stratified by
tuberculosis prevalence
The median prevalence of tuberculosis in studies with sympto-
matic participants was 43% (interquartile range (IQR) 32% to 60%).
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In an analysis by tuberculosis prevalence, we found that pooled
sensitivity and specificity for symptomatic participants in settings
with tuberculosis prevalence of greater than 43% were 44% (27% to
62%) and 86% (73% to 94%) and 39% (21% to 63%) and 95% (89%
to 97%) in settings with a tuberculosis prevalence less than 43%.
Sensitivity analyses
In evaluation of the accuracy of LF-LAM for detection of tuberculo-
sis, we undertook sensitivity analyses by limiting inclusion in the
meta-analysis to the following.
• Studies with low risk of bias for patient selection (two studies)• Studies with low risk of bias in the reference standard domain
(one study)• Studies that used fresh urine samples (four studies) rather than
stored urine sample
Two studies with greater than 80% symptomatic participants (Bjer-
rum 2015; Lawn 2017) were re-assigned from ‘studies of unselected
participants' to ‘studies of symptomatic participants'.
These sensitivity analyses only included few studies and partici-
pants and made little difference to any of the findings (Table 3).
II. Diagnostic accuracy of LF-LAM for tuberculosis diagnosis
in HIV-positive unselected adults irrespective of signs and
symptoms for tuberculosis
Of the 15 studies included, seven studies evaluated the accura-
cy of LF-LAM for diagnosis in participants, irrespective of sign and
symptoms (‘unselected participants’) (Bjerrum 2015; Drain 2015a;
Floridia 2017; Hanifa 2016; LaCourse 2016; Lawn 2017; Thit 2017).
The tuberculosis prevalence in the study population varied from
1% in LaCourse 2016 to 33% in Lawn 2017. Six of the studies report-
ed the proportion of symptomatic participants that were included
(e.g. having a positive WHO symptoms screen) which varied from
19% (LaCourse 2016) to more than 90% of participants in two stud-
ies (Bjerrum 2015; Lawn 2017). No studies reported results specif-
ically for individuals who were asymptomatic. Four studies were
carried out in an outpatient setting (Drain 2015a; Floridia 2017;
Hanifa 2016; LaCourse 2016), one study exclusively in an inpatient
setting (Lawn 2017), and two studies in both inpatient and outpa-
tient settings (Bjerrum 2015; Thit 2017). The median CD4 cell count
across studies of unselected adults ranged from 111 to 437 cells per
µL across studies. See Table 1 and Characteristics of included stud-
ies.
Primary analysis, LF-LAM for tuberculosis in HIV-positive adults
irrespective of signs and symptoms of tuberculosis
For determining the overall accuracy of LF-LAM in HIV-positive
adults irrespective of signs and symptoms of tuberculosis, seven
studies provided data for 3365 participants, including 432 (13%)
with tuberculosis. Sensitivity estimates ranged from 0% to 67%,
and specificity estimates from 64% to 99% (Figure 8).
 
Figure 8.   Forest plots of LF-LAM sensitivity and specificity for tuberculosis against a microbiological reference
standard for studies among unselected participants not assessed for signs and symptoms of tuberculosis. The
individual studies are ordered by decreasing sensitivity. TP = True Positive; FP = False Positive; FN = False Negative;
TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure
shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).
 
Sensitivity was lowest (0%) in LaCourse 2016, that differed from the
other studies by including a) a population of exclusively pregnant
women attending an antenatal care setting, b) a low proportion of
symptomatic participants (19%), c) a low tuberculosis prevalence
(1%), and d) a high median CD4 cell count (437 cells per µL). Speci-
ficity was lowest (64%) in the study by Thit 2017 that also reported
the highest sensitivity (67%). This study reported that more than
90% of the FP results were grade 1 positive results (classified as pos-
itive according to current manufacturer recommendations). Partic-
ipants included had a median CD4 at 270 cells per μL and 33% were
symptomatic at enrolment. The study evaluated sputum samples
only and allowed a follow-up for six months from LF-LAM testing
at enrolment to final classification of participants as ‘Tuberculosis'
or ‘Not tuberculosis' cases. Thit 2017 further differed from the oth-
er studies by being conducted in Myanmar, and is the only study
included in this review that evaluated LF-LAM in a setting outside
sub-Saharan Africa. The pooled sensitivity and specificity (95% CrI)
were 35% (22% to 50%) and 95% (89% to 98%) (Table 2). Appendix
9 presents the pooled and predicted sensitivity and specificity esti-
mates together with the credible and prediction regions for LF-LAM
for tuberculosis detection. Prediction intervals were very wide in
all meta-analysis models indicating between-study heterogeneity
(data not shown).
Uninterpretable index test results
The included studies reported no uninterpretable results.
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Investigations of heterogeneity
LF-LAM accuracy among unselected participants, stratified by setting
LF-LAM accuracy in inpatient settings
We identified three studies that evaluated accuracy among inpa-
tients involving 537 participants, 159 (30%) with tuberculosis (Bjer-
rum 2015; Lawn 2017; Thit 2017). Sensitivity estimates ranged from
39% to 88% and specificity estimates ranged from 39% to 99% (Fig-
ure 9).
 
Figure 9.   Forest plots of LF-LAM sensitivity and specificity for tuberculosis against a microbiological reference
standard for studies among unselected participants, by health care setting. TP = True Positive; FP = False Positive;
FN = False Negative; TN = True Negative. The individual studies are ordered by decreasing sensitivity. Between
brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated
sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).
 
Thit 2017 reported a very low specificity (39%) and a high sensitivity
(88%), based on a relatively small sample size of 54 inpatients; eight
(15%) with tuberculosis. The authors reported that 41 of the inpa-
tients (76%) were symptomatic at enrolment with a median CD4 of
96 (IQR 37 to 277) cells per µL, which is comparable to evaluation of
LF-LAM in a population with advanced HIV disease. The study fur-
ther differed from the other studies by allowing a follow-up for six
months for classification of participants and by being conducted in
Myanmar as mentioned above. Most of the participants (91%) in-
cluded in the studies by Bjerrum 2015 and Lawn 2017 were symp-
tomatic and thus comparable to studies with symptomatic partic-
ipants. See Table 1 and Characteristics of included studies. The
pooled sensitivity and specificity (95% CrI) among unselected inpa-
tients were 62% (41% to 83%) and 84% (48% to 96%) (Table 2).
LF-LAM accuracy in outpatient settings
Six studies were conducted among unselected outpatients, involv-
ing 2828 participants; 273 (10%) with tuberculosis (Bjerrum 2015;
Drain 2015a; Floridia 2017; Hanifa 2016; LaCourse 2016; Thit 2017).
Sensitivity estimates ranged from 0% to 63% and specificity esti-
mates ranged from 67% to 99% (Figure 9). Pooled sensitivity and
specificity (95% CrI) were 31% (18% to 47%) and 95% (87% to 99%)
(Table 2).
LF-LAM accuracy among unselected participants, stratified by CD4
count
There were limited data to evaluate LF-LAM by CD4 threshold for
unselected participants. Five studies contributed data to the analy-
ses by CD4 count (Bjerrum 2015; Drain 2015a; Hanifa 2016; La-
Course 2016; Lawn 2017). See Appendix 10; Appendix 11 and Table
2.
LF-LAM accuracy stratified by CD4 ≤ 200 cells per µL and > 200 cells per
µL
Two studies evaluated LF-LAM in unselected participants with CD4
≤ 200 cells per µL, all settings. Sensitivity and specificity were 45%
and 93% for Bjerrum 2015, and 7% and 99% for Hanifa 2016, (Ap-
pendix 10). Pooled sensitivity and specificity were 26% (9% to 56%)
and 96% (87% to 98%) (706 participants, 12% with tuberculosis)
(Table 2).
For unselected outpatients with a CD4≤ 200 cells per µL, two stud-
ies contributed data (652 participants; 10% with tuberculosis). Sen-
sitivity and specificity were 36% and 94% for Bjerrum 2015, and
7% and 99% for Hanifa 2016 (Appendix 10). Pooled sensitivity and
specificity were 21% (8% to 48%) and 96% (89% to 99%) (Table 2).
When we limited the analysis to unselected inpatients with CD4 ≤
200 cells per µL, only one study (Bjerrum 2015) contributed data
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and found a sensitivity of 64% (95% CI: 35% to 87%) and specificity
of 82% (67% to 93%) (54 participants, 26% with tuberculosis).
For comparison, we assessed diagnostic accuracy among partici-
pants with CD4 > 200 cells per µL, all settings. Only one study re-
ported data for participants with CD4 > 200 cells per µL and report-
ed a sensitivity of 27% (95% CI: 6% to 61%) and specificity of 99%
(95% CI; 96% to 100%) (Bjerrum 2015).
LF-LAM accuracy stratified by CD4 ≤ 100 cells per µL and > 100 cells per
µL
Three studies evaluated patients with CD4 ≤ 100 cells per µL, all set-
tings, and sensitivity estimates ranged from 37% to 55% and speci-
ficity from 80% to 98% (Appendix 11). The pooled sensitivity and
specificity (95% CrI) among participants with CD4 ≤ 100 cells per µL
were 47% (30% to 64%) and 90% (77% to 96%) (3 studies, 417 par-
ticipants, 31% with tuberculosis) (Table 2).
When we limited the analysis to studies involving unselected in-
patients with CD4 ≤ 100 cells per µL two studies contributed data,
(200 participants; 42% with tuberculosis). Sensitivity and specifici-
ty were 60% and 80% for Bjerrum 2015, and 55% and 98% for Lawn
2017 (Appendix 11). The pooled sensitivity and specificity were 57%
(33% to 79%) and 90% (69% to 97%) (Table 2).
Two studies contributed data for unselected outpatients with CD4
≤ 100 cells per µL (Bjerrum 2015; Hanifa 2016) (Appendix 11). The
pooled sensitivity and specificity were 40% (20% to 64%) and 87%
(68% to 94%) (217 participants, 21% with tuberculosis) (Table 2).
Four studies evaluated LF-LAM in participants with CD4 > 100 cells
per µL (Bjerrum 2015; Drain 2015a; LaCourse 2016; Lawn 2017).
Sensitivity estimates ranged from 0% to 33% and specificity esti-
mates ranged from 95% to 99% (Appendix 11). Pooled sensitivity
and specificity (95% CrI) were 20% (10% to 35%) and 98% (95% to
99%), (952 participants, 12% with tuberculosis) (Table 2).
LF-LAM accuracy among unselected participants, stratified by
tuberculosis prevalence
The median prevalence of tuberculosis in studies with unselected
participants was 10% (IQR 9% to 17%). In the analysis by tuberculo-
sis prevalence, we found that pooled sensitivity and specificity for
unselected participants in settings with tuberculosis prevalence of
10% or more were 45% (31% to 61%) and 92% (79% to 97%) (4 stud-
ies) compared to 16% (5% to 36%) and 98% (94% to 99%) in settings
with tuberculosis prevalence less than 10% (3 studies). In general,
tuberculosis prevalence increased in studies with a higher propor-
tion of symptomatic participants.
Sensitivity analyses
As for studies among symptomatic participants, we undertook sen-
sitivity analyses by limiting inclusion in the meta-analysis to the fol-
lowing.
• Studies with low risk of bias for patient selection (three studies)• Studies with low risk of bias in the reference standard domain
(two studies)• Studies that used fresh urine samples (five studies) rather than
stored urine sample
We further excluded the two studies with more than 80% of partic-
ipants being symptomatic at inclusion (Bjerrum 2015; Lawn 2017).
These sensitivity analyses made little difference to any of the find-
ings (Table 3).
D I S C U S S I O N
This systematic review updates the current literature and includes
15 unique studies on the accuracy of lateral flow urine lipoara-
binomannan assay (LF-LAM, Alere Determine™ TB LAM Ag) for tu-
berculosis in adults living with HIV and integrates nine new stud-
ies identified since the original WHO guidelines (WHO Lipoarabino-
mannan Policy Guidance 2015) and Cochrane Review (Shah 2016).
A priori, we chose to evaluate performance of LF-LAM separately for
studies that enrolled strictly symptomatic participants and studies
that enrolled unselected participants irrespective of signs and/or
symptoms of tuberculosis, and we conducted investigations of het-
erogeneity based on CD4 counts and study setting (inpatient/out-
patient). Eight studies used LF-LAM for tuberculosis diagnosis in
symptomatic adult participants with signs and symptoms sugges-
tive of tuberculosis. These studies largely focused on inpatient set-
tings and had high tuberculosis prevalence. Seven studies evaluat-
ed LF-LAM for diagnosing tuberculosis in unselected participants
who may or may not have had signs or symptoms suggestive of tu-
berculosis when enrolled in the study. The studies with unselect-
ed participant were conducted predominantly in outpatient set-
tings and, compared to studies with exclusively symptomatic par-
ticipants, had lower tuberculosis prevalence and involved patients
with higher CD4 counts; the proportion of symptomatic partici-
pants in these studies ranged from 19% to 90%. All studies were
conducted in low- and middle-income countries with a high tuber-
culosis/HIV burden, and only one study outside sub-Saharan Africa.
Summary of main results
We have summarized the main findings in Summary of findings 1;
Summary of findings 2. The main findings of this updated review
include the following.
For tuberculosis diagnosis in HIV-positive adults presenting with
signs and symptoms of tuberculosis, the diagnostic accuracy of LF-
LAM is (95% credible interval (CrI)):
• In all settings, sensitivity 42% (31% to 55%) and specificity 91%
(85% to 95%);• In inpatient settings, sensitivity 52% (40% to 64%) and specifici-
ty 87% (78% to 93%);• In outpatient settings, sensitivity 29% (17% to 47%) and speci-
ficity 96% (91% to 99%).
For tuberculosis diagnosis in HIV-positive adults irrespective of
signs and symptoms of tuberculosis, the diagnostic accuracy of LF-
LAM is:
• In all settings, sensitivity 35% (22% to 50%) and specificity 95%
(89% to 98%);• In inpatient settings, sensitivity 62% (41% to 83%) and specifici-
ty 84% (48% to 96%);• In outpatient settings, sensitivity 31% (18% to 47%) and speci-
ficity 95% (87% to 99%).
We note that the band intensity of grade 1 in this review corre-
sponds to the current manufacturer threshold for positivity (equiv-
alent to that of grade 2 on the old manufacturer reference card) and
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all results were evaluated against a microbiological reference stan-
dard.
LF-LAM for tuberculosis diagnosis in studies with symptomatic
participants
Summary of findings 1.
In planned investigations of heterogeneity, we found an inverse
correlation between LF-LAM sensitivity and CD4 count, with in-
creasing sensitivity as patient CD4 count decreased (increased from
16% (CrI 8% to 31%) in patients with CD4 cell count > 200 cells per
µL to 24% (CrI 14% to 38%) in patients with CD4 cell count between
101 to 199 cells per µL, to 54% (CrI 38% to 69%) in patients with
CD4 ≤ 100 cells per µL). Similarly, we a priori planned to investigate
and expected to find higher sensitivity in patients who were hospi-
talized while specificity decreased.
Results of these studies indicate that in theory, for a population of
1000 people where 300 have microbiologically-confirmed tubercu-
losis, the utilization of LF-LAM would result in: 189 to be LF-LAM
positive: of these, 63 (33%) would not have tuberculosis (false-pos-
itives); and 811 to be LF-LAM negative: of these, 174 (21%) would
have tuberculosis (false-negatives).
LF-LAM for tuberculosis diagnosis in studies with unselected
participants (signs and symptoms not assessed as a condition
of study inclusion)
Summary of findings 2.
In the investigations of heterogeneity, we expected and found a
higher sensitivity in patients with CD4 ≤ 100 cells per µL (47%) and
among inpatients (62%) compared to patients with CD4 > 100 cells
per µL (20%) among outpatients (31%) respectively, though da-
ta to inform subgroup analyses were limited. We noted that par-
ticipants included in the studies with unselected participants of-
ten presented with sign and symptoms suggestive of tuberculosis
(a positive WHO tuberculosis screen), and in the studies evaluat-
ing inpatients most participants (> 80%) were in fact presenting
with signs and symptoms suggestive of tuberculosis. These studies
may be considered more similar to studies with exclusively symp-
tomatic participants. In additional analysis of heterogeneity, we
examined diagnostic accuracy based on tuberculosis prevalence
within the studied cohort, as an alternative surrogate to presence
of symptoms or CD4 count as an assessment of pre-test probability.
We found that pooled sensitivity was 45% when tuberculosis preva-
lence within the study population was ≥ 10%, compared to only
16% when tuberculosis prevalence in the study population was <
10%.
Results of these studies indicate that in theory, for a population
of 1000 people where 100 have microbiologically-confirmed tuber-
culosis, the utilization of LF-LAM would result in: 80 to be LF-LAM
positive: of these, 45 (56%) would not have tuberculosis (false-pos-
itives); and 920 to be LF-LAM negative: of these, 65 (7%) would have
tuberculosis (false-negatives).
LF-LAM for tuberculosis diagnosis, overall
The findings of this updated review are consistent with those of the
original review (Shah 2016; WHO Lipoarabinomannan Policy Guid-
ance 2015). Inclusion of additional studies in this updated review
provided the basis for a more precise estimate of the LF-LAM over-
all sensitivity and specificity. It further allowed us to address key
questions regarding test accuracy and sources of heterogeneity in-
cluding clinical setting and CD4 cell count in studies with sympto-
matic individuals and in studies with unselected participants.
Overall, we found lower sensitivity for diagnosis of tuberculosis
among people living with HIV than the internationally suggested
target of minimum 65% overall for rapid non-sputum tuberculosis
tests (WHO TTP 2014). We found that sensitivity increased when
considering inpatients and individuals with lower CD4 counts,
whether considering studies with exclusively symptomatic partic-
ipants or those with unselected participants. The reasons for this
heterogeneity remain unclear, and several hypotheses have been
postulated including differences in bacterial burden, sites of tuber-
culosis disease, or degree of glomerular dysfunction that may be
different across different settings or CD4 counts.
When restricting analysis to studies that included participants un-
able to produce a sputum sample, the estimates of sensitivity in-
creased. Sputum-scarce patients may be the potential target pop-
ulation to benefit the most from urine-based testing as they can-
not have other sputum-based diagnostic testing and are likely to
have a high yield of urine lipoarabinomannan (LAM) test positiv-
ity (Sabur 2017). However, only a few studies included partici-
pants who could not provide sputum samples for diagnostic test-
ing. To the extent that inability to produce sputum is correlated
with severity of tuberculosis disease and/or LAM positivity, this ap-
proach to participant selection could have lowered sensitivity esti-
mates within these studies. Sensitivity analysis further revealed a
higher sensitivity among studies evaluating LF-LAM on fresh non-
stored urine samples without it affecting specificity. However, no
study has made a direct comparison of performance on fresh versus
frozen/stored urine samples and the significance of this is unclear.
Overall, we found that the estimated specificity approached the
recommended targets for non-site-specific, non-sputum based test
(WHO TTP 2014), although lower specificity was found among inpa-
tients and those with advanced immunosuppression compared to
outpatients and those with higher CD4 counts. We expected that, if
restricting the analysis to studies using a higher quality reference
standard (e.g. inclusion of more than one specimen type), that esti-
mates of specificity would increase, but had limited data to conduct
such a sensitivity analysis. When evaluating an assay that is not site-
specific, future studies may consider systematic sampling of mul-
tiple sites to improve the quality of the reference standard. Future
studies should include systematic sampling of sputum, blood, and
urine for mycobacterial culture and/or nucleic acid amplification
test (NAAT) testing from all participants as common sites of tuber-
culosis that may be identified by urinary LAM antigen detection; ad-
ditional site-specific samples (e.g. cerebrospinal fluid (CSF), tissue
biopsies) should also be collected for culture and/or NAAT based on
clinical presentation.
We decided a priori to evaluate performance of LF-LAM in HIV-pos-
itive individuals with signs and symptoms of tuberculosis (sympto-
matic) separately from HIV-positive individuals irrespective of signs
and symptoms of tuberculosis (unselected participants). We con-
sidered evaluating LF-LAM performance among specifically asymp-
tomatic (i.e. exclusively those without symptoms) participants to
assess the use of LF-LAM for the purpose of tuberculosis screening
or community-based active case-finding, but such data were lack-
ing among included studies. We did find that several studies among
unselected participants reported that a high proportion of study
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participants had signs and symptoms of tuberculosis, suggesting
relative similarities to studies that enrolled exclusively sympto-
matic participants. Consequently, the overall performance of LF-
LAM among asymptomatic patients remains largely unknown.
The overall differences in pooled estimates of sensitivity and speci-
ficity between studies of symptomatic versus unselected partici-
pants may have been attributable to differences in study setting
and relative degree of immunosuppression of included partici-
pants, rather than type of population (i.e. unselected versus symp-
tomatic participants). When examining inpatients, the pooled esti-
mates for sensitivity were 52% (40% to 64%) and 62% (41% to 83%),
when comparing studies of symptomatic participants and those
including unselected participants. Among outpatients, the pooled
sensitivity was 29% (17% to 47%) compared to 31% (18% to 47%)
among studies of symptomatic participants and unselected partic-
ipants, respectively. This indicates that other characteristics than
lower CD4 may explain the higher sensitivity among inpatients like
higher tuberculosis prevalence, higher mycobacterial burden, re-
nal or genitourinary tract tuberculosis with LAM secretion in urine.
Overall, our findings suggest that the diagnostic accuracy of LF-LAM
may vary by study setting, CD4 count, and tuberculosis prevalence
among the target population. The authors hypothesize that these
attributes (inpatients, low CD4 counts, or high tuberculosis preva-
lence) may collectively be surrogate indicators of participants with
advanced tuberculosis disease or higher bacillary burden and LAM
antigenuria in whom LF-LAM may aid in the diagnosis of tuber-
culosis, including both pulmonary and extrapulmonary tubercu-
losis. Although subgroup comparisons in diagnostic accuracy re-
views are observational and suffer from the same limitations as all
observational findings (for example, confounding between charac-
teristics), there is a scientific rationale for these finding in that in-
patients, those with low CD4, or cohorts with higher tuberculosis
prevalence are likely to have higher disease severity or higher bacil-
lary burden. While the test does not identify all tuberculosis cases,
our findings suggest that it may be of particular value in diagnosing
tuberculosis among patients with increased disease severity. Other
factors that may be considered in evaluating LF-LAM may include
ability to perform the test on individuals unable to produce sputum
who cannot be diagnosed with other tuberculosis diagnostic tests,
and ability to implement the test at the point-of-care with non-in-
vasive specimen collection (WHO TTP 2014).
We identified three published studies of LF-LAM in children as
the result of a broader search for studies in adults and children
using the same inclusion criteria (Kroidl 2015; LaCourse 2018a;
Nicol 2014). All three studies took place in countries in Africa
with a high tuberculosis/HIV burden. Prevalence of microbiolog-
ically-confirmed tuberculosis in the studies was 7% in LaCourse
2018a, 22% in Nicol 2014; and 40% in Kroidl 2015. Kroidl 2015 en-
rolled children six weeks to 14 years, median age (interquartile
range (IQR)) 6.8 years (3.9 to 9.5) for all participants, including HIV-
positive and HIV-negative children. LaCourse 2018a enrolled chil-
dren aged 12 years or less, median age (IQR) 24 months (13 to 58).
Nicol 2014 enrolled children aged 15 years or less, median age (IQR)
42.5 months (19.1 to 66.3) for all participants, including HIV-pos-
itive and HIV-negative children. A table summarizing the charac-
teristics of studies in children can be found in Appendix 12. Kroidl
2015 and Nicol 2014 involved HIV-positive children with tuberculo-
sis symptoms. LaCourse 2018a involved HIV-positive children hos-
pitalized for acute illness irrespective of tuberculosis signs and
symptoms. Kroidl 2015 was conducted in an outpatient setting, La-
Course 2018a in an inpatient setting, and Nicol 2014 in both an in-
patient and an outpatient setting (Appendix 12). Given the differ-
ences in population and setting, we did not perform meta-analy-
ses and report sensitivity and specificity estimates for the individ-
ual studies, all measured against a microbiological reference stan-
dard. Sensitivity and specificity (95% CI) were 42% (15% to 72%)
and 94% (73% to 100%), (30 participants) (Kroidl 2015); 56% (21%
to 86%) and 95% (90% to 98%), (130 participants) (LaCourse 2018a);
and 43% (23% to 66%) and 80% (69% to 88%), (106 participants)
(Nicol 2014). We found limited evidence on the accuracy of LF-LAM
in children living with HIV. There were too few studies and partici-
pants to draw conclusions.
We acknowledge that patient outcomes are clearly important to
patients, decision makers, and the wider tuberculosis communi-
ty. While, the primary focus of this Cochrane Review update was
to evaluate the diagnostic accuracy of LF-LAM, in the process of
performing the review, we also assessed available data on LF-LAM
and patient-important outcomes including mortality. We identified
two randomized controlled trials (Gupta-Wright, 2018a; Peter 2016)
that included data on the impact of LF-LAM implementation on
mortality and other patient outcomes. Peter 2016 enrolled partic-
ipants with tuberculosis symptoms, and Gupta-Wright, 2018a en-
rolled unselected participants irrespective of symptoms. Both tri-
als were conducted in multiple countries in sub-Saharan Africa.
Both trials involved hospitalized, HIV-positive patients, used the re-
sults of LF-LAM to guide therapy, and assessed all-cause mortali-
ty at eight weeks. Peter 2016 found that mortality was significant-
ly reduced in participants receiving LF-LAM compared to those re-
ceiving routine diagnostic tests alone (no LF-LAM); adjusted rela-
tive risk reduction of 0.83 (95% CI: 0.73 to 0.96, P = 0.012). In Gup-
ta-Wright, 2018a, the use of rapid urine screening with LF-LAM and
urine Xpert MTB/RIF (intervention group) was not associated with
a statistically significant reduction in mortality compared with rou-
tine diagnostic tests alone (standard-of-care group, no LF-LAM); ad-
justed risk reduction (aRD) of -2.8% (95% CI -5.8 to 0.3, P = 0.074).
However, of importance, Gupta-Wright, 2018a, demonstrated that
mortality was significantly lower in the intervention group than in
the standard-of-care group for three of 12 prespecified subgroups:
CD4 counts less than 100 cells per μL (aRD -7.1% (95% CI -13.7 to
-0.4), P = 0.036); severe anaemia (aRD -9.0% (95% CI -16.6 to -1.3),
P = 0.021); and participants with clinically suspected tuberculosis
(aRD -5.7% (95% CI -10.9 to -0.5), P = 0.033). We will address the im-
pact of testing with LF-LAM on patient outcomes in greater depth
in another Cochrane Review (a Cochrane Protocol is underway).
Concerning economic evaluations, we are aware of six studies, all
from settings in sub-Saharan Africa (Boyles 2018; Mukora 2018;
Orlando 2018; Reddy 2019; Shah 2013; Sun 2013). These study
methods and populations were heterogeneous, assessing a range
of diagnostic algorithms, and only four of the total studies as-
sessed cost-effectiveness (Orlando 2018; Reddy 2019; Shah 2013;
Sun 2013), while Mukora 2018 performed a detailed costing study,
including both at clinical and above clinic level costs, and Boyles
2018 assessed whether the addition of LF-LAM in diagnostic algo-
rithms could reduce total program costs. studies employed a range
of different willingness to pay thresholds, all four studies were con-
sistent in concluding LF-LAM could be cost-effective in a population
of African adults living with HIV (particularly amongst hospitalized
patients). Models found cost-effectiveness of LF-LAM to be robust
across a variety of sensitivity analyses, and across different country
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settings and scenarios investigated. Key parameters that are likely
most influential on cost-effectiveness include: tuberculosis preva-
lence/target population, and LF-LAM specificity, cost of treating tu-
berculosis and HIV and life expectancy post tuberculosis survival.
Detailed empirical costing data are limited for LF-LAM implemen-
tation, however one such study published in 2018 (Mukora 2018)
estimates unit test costs for LF-LAM implementation several fold
higher (˜$23-24) than most current models ($2-4), where costs of
implementation and staS time are not considered. Underestima-
tion of LF-LAM unit costs could result in overly optimistic cost-ef-
fectiveness profiles. However, tuberculosis diagnostics costs likely
represent just a small proportion of total costs, indeed inclusion of
costs associated with antiretroviral treatment (ART) and HIV care
resulted in higher incremental cost-effectiveness ratios. While cur-
rent evidence is consistent in suggesting LF-LAM is likely cost-ef-
fective among HIV-positive patients in sub-Saharan Africa, caution
should be used when extrapolating from a small number of studies,
and additional evidence from a wider range of populations, settings
and diagnostic approaches will be necessary. A systematic review
of economic evaluations is underway.
DiOerences from original Cochrane Review
In comparison to the original Cochrane Review (Shah 2016), this up-
dated review includes 15 published studies (nine new studies since
the original review and six studies from the original review). The
original review included data from 12 studies, of which six were ex-
cluded as they did not meet the eligibility criteria for this updat-
ed review. Three used an older threshold for determining test pos-
itivity that is no longer recommended and three were abstracts, of
which one (Lawn 2014) was added in this review as an updated pub-
lished manuscript. For comparison, the main findings from the orig-
inal review (Shah 2016) are listed in Table 4.
In the evaluation of diagnostic accuracy among symptomatic par-
ticipants, the pooled estimates for sensitivity (42% [CrI 31% to 55%]
versus 45% [CrI 29% to 63%]) and specificity (91% [CrI 85% to 95%]
versus 92% [CrI 80% to 97%]) remained similar, comparing the cur-
rent review and prior review, respectively. When stratified by set-
ting, the pooled estimates among inpatients for sensitivity (52%
[CrI 40% to 64%] versus 53% [CrI 38% to 70%)]) and specificity (87%
[CrI 78% to 93%] versus 90% [CrI 73% to 96%]) did not change sub-
stantially when comparing the current review and the prior review,
respectively. Pooled estimates among outpatients at the current
manufacturer threshold for positivity were not previously avail-
able.
In Shah 2016, some studies were classified as ‘tuberculosis (TB)
screening’ if they included participants irrespective of symptoms
(i.e. with or without symptoms). Recognizing that these studies
may have included a large proportion of symptomatic participants,
these studies have been more clearly labelled as studies among
‘unselected participants’ in the current review. In the prior review,
there were insufficient data to perform meta-analysis among uns-
elected participants at the currently recommended manufacturer
threshold for test positivity. There were previously insufficient da-
ta to investigate heterogeneity due to study setting or CD4 count.
In the current review, we report on diagnostic accuracy among in-
patients and outpatients and by CD4. In both the current and prior
review, data to assess diagnostic accuracy among asymptomatic
participants (without signs or symptoms of tuberculosis) were un-
available.
This updated review did not assess diagnostic accuracy at an older
threshold for determining test positivity (grade 1 out of 5, on an old-
er reference card); data on diagnostic accuracy for this threshold
can be found in the prior review (Shah 2016). Similarly, in this up-
dated review we did not evaluate accuracy against a composite ref-
erence standard, results of which were included in the prior review
(Shah 2016). Finally, given the relative lack of data on evaluating
the incremental yield of LF-LAM in combination with sputum smear
microscopy and Xpert MTB/RIF, we did not include these analyses
in the updated review, but a summary of available data is found in
the prior review (Shah 2016).
We note that the band intensity of grade 1 in this review corre-
sponds to the current manufacturer threshold for positivity (equiv-
alent to that of grade 2 on the old manufacturer reference card) and
all results were evaluated against a microbiological reference stan-
dard.
Strengths and weaknesses of the review
The findings in this review are based on comprehensive search-
ing, strict inclusion criteria, and standardized data extraction. The
strength of our review is that it enabled an assessment of the ac-
curacy of LF-LAM in people living with HIV when applied to differ-
ent enrolment criteria - accuracy among individuals with signs and
symptoms of tuberculosis, and accuracy when used without as-
sessment of signs and symptoms of tuberculosis (i.e. patients may
or may not have had symptoms). This updated review included
new studies published since the original review. However, we found
considerable heterogeneity across studies with respect to clinical
setting, CD4 count and tuberculosis prevalence. For some analyses,
few studies and participants contributed data and results should,
therefore, be interpreted with caution. The review was further lim-
ited by the number of studies that used a lower quality reference
standard and the high risk of selection bias in several studies owing
to exclusion of patients unable to produce sputum.
Completeness of evidence
This data set involved comprehensive searching and correspon-
dence with experts in the field and the test manufacturer to identi-
fy additional studies, as well as correspondence with study authors
to obtain additional and unpublished data on study characteristics.
The search strategy included studies published in all languages.
However, as diagnostic accuracy studies are poorly indexed, we
acknowledge that we may have missed some studies despite the
comprehensive search.
Accuracy of the reference standards used
In a diagnostic test accuracy systematic review, the reference stan-
dard is the best available test to determine the presence or ab-
sence of the target condition. We only included studies with a mi-
crobiological reference standard, which is considered the best cur-
rently available reference standard for tuberculosis. We included
studies that evaluated LF-LAM for diagnosis of pulmonary tuber-
culosis, extrapulmonary tuberculosis, or both pulmonary and ex-
trapulmonary tuberculosis. However, we recognize that a substan-
tial number of tuberculosis cases may not be verified by microbio-
logical testing if only sputum is tested and when patients with ad-
vanced HIV are assessed. We acknowledge difficulties in diagnos-
ing HIV-associated tuberculosis with extrapulmonary and dissem-
inated forms of disease and considered a standardized reference
standard using two or more specimen types consistently for all par-
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ticipants to be of higher quality than a reference standard using
one specimen type. The higher quality reference standard is bet-
ter at classifying which patients have and do not have tuberculo-
sis. A lower quality reference standard may miss some tuberculosis
cases and classify some tuberculosis patients as not having tuber-
culosis. This may make a truly positive LF-LAM result seem like a
false-positive result leading to an underestimation of specificity. In
this review, only one study (12%) for tuberculosis diagnosis among
symptomatic participants and two studies (29%) for tuberculosis
diagnosis among unselected participants used a higher quality ref-
erence standard for all participants.
We did not assess performance against a composite reference stan-
dard that uses microbiological or clinical information to classify
tuberculosis. This was done in the original WHO guideline (WHO
Lipoarabinomannan Policy Guidance 2015), and Cochrane Review
((Shah 2016), but found little impact on pooled estimates of sen-
sitivity and specificity relative to performance measured against a
microbiological reference standard.
We could not determine whether heterogeneity in specificity esti-
mates was fully attributable to misclassification bias. Some stud-
ies (Nel 2017; Qvist 2014) have postulated that infection with (dis-
seminated) nontuberculous mycobacteria (NTM) may also result in
false-positive results, although this hypothesis is still questioned
(Gupta-Wright 2018). Only one study (Thit 2017) was conducted
outside of sub-Saharan Africa, and was noted to report the low-
est specificity estimates of all included studies. Reasons for poten-
tial false-positive results remain unclear and it is unknown if differ-
ences in the epidemiology of disseminated NTM and other oppor-
tunistic infections across settings could contribute to variation in
specificity.
Quality and quality of reporting of the included studies
There were few studies that included participants unable to expec-
torate sputum and few studies that included extrapulmonary spec-
imens in addition to sputum. We had limited data to address these
quality items in sensitivity analyses and acknowledge that these
features may have contributed to risk of bias in the accuracy esti-
mates. For studies among symptomatic participants, in the patient
selection domain, we considered six studies (75%) to be at high risk
of bias, and in the reference standard domain, we considered seven
studies (88%) to be at high risk of bias. For studies with unselected
participants, in the patient selection domain, we considered four
studies (57%) to be at high risk of bias and in the reference standard
domain, we considered five studies (71%) to be at high risk of bias.
Risk of bias was considered low for the index test and flow and tim-
ing domains.
Using the GRADE approach, we judged the evidence for LF-LAM sen-
sitivity to be moderate. This means that we are moderately confi-
dent in the effect estimate: the true effect is likely to be close to the
estimate of the effect, but there is a possibility that it is substantial-
ly different. We judged the evidence for LF-LAM specificity to be low
or very low. This means that we have very little confidence in the
effect estimate: the true effect is likely to be substantially different
from the estimate of effect.
In general, studies were fairly well reported, though we corre-
sponded with some of the primary study authors to ask for clarifi-
cation mainly in relation to interpretation of test positivity.
Applicability of findings to the review question
Overall, we had low concern about the applicability of the includ-
ed studies to our review question as assessed by Quality Assess-
ment of Diagnostic Accuracy Studies-2 (QUADAS-2). However, stud-
ies of HIV-positive adults irrespective of signs and symptoms had
low representation of asymptomatic individuals, as most partic-
ipants in fact presented with signs and symptoms of tuberculo-
sis. To date, no study has evaluated LF-LAM in an asymptomatic
population. This review evaluated LF-LAM at the current manufac-
turer-recommended cut-oS for positivity. Therefore, the findings
should be considered applicable to the test. However, it is impor-
tant to note that this review assessed sensitivity and specificity in
applied research settings. Although the participant characteristics
and settings matched our review question in most cases, as stud-
ies were carried out under research conditions, it is possible that
the accuracy of LF-LAM may be lower in routine practice settings.
All studies were performed in low- or middle-income countries, but
only a single study was conducted outside sub-Saharan Africa. It
is therefore possible that the LF-LAM would perform differently in
settings outside Africa. For the reference test domain, most studies
had low concern for applicability.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
For people living with HIV, this review found overall lower sensi-
tivity of the lateral flow urine lipoarabinomannan assay (LF-LAM)
than the internationally suggested target of minimum 65% over-
all for non-sputum based tuberculosis diagnostic tests (WHO TTP
2014). This was consistent whether the test is used for diagnosis of
HIV-associated tuberculosis (without consideration of sites of dis-
ease involvement) among symptomatic (sensitivity of 42%) or un-
selected (i.e. not assessed for symptoms) participants (sensitivity
of 35%). The estimated sensitivity suggests that if LF-LAM were to
be used alone, more than half of all tuberculosis cases would be
missed. Whether diagnostic accuracy differs for specific sites of tu-
berculosis is unknown (e.g. pulmonary tuberculosis, tuberculosis
meningitis, or lymph node tuberculosis). There was a lack of data
to evaluate diagnostic accuracy for active tuberculosis in asympto-
matic participants, but studies among unselected outpatients that
included a combination of symptomatic and asymptomatic partici-
pants (i.e. unselected participants) showed lower sensitivity (31%).
Despite the estimated sensitivity, two randomized controlled trials
implementing LF-LAM in high-prevalence settings in sub-Saharan
Africa have demonstrated reduced mortality and impact on oth-
er clinical outcomes when used to guide tuberculosis treatment in
hospitalized HIV-positive adults.
LF-LAM is being considered as a diagnostic test that may be used as
an add on to clinical judgement and with other tests for the diagno-
sis of HIV-associated tuberculosis. The test does not have a role as a
replacement or triage test. The test may improve important health
outcomes among HIV-positive hospitalized patients because it is
feasible (i.e. can be done on urine which is easy to obtain in an in-
patient) and may yield a positive result in those that are most like-
ly to die from tuberculosis and are most likely to present atypically
(i.e. patients with advanced HIV). Whether these results may be ex-
trapolated to outpatients with advanced HIV disease or those that
are seriously ill is unknown.
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Findings suggest that sensitivity increases with lower CD4 counts
and in inpatient settings compared to outpatient settings. For un-
selected participants irrespective of symptoms, we found differ-
ences in LF-LAM performance based on tuberculosis prevalence of
the target population (when stratified at greater or less than 10%),
with higher sensitivity when the study population had higher tuber-
culosis prevalence (≥ 10%). The difference in diagnostic accuracy of
LF-LAM by study setting and by degree of immunosuppression was
consistent regardless of the approach to patient selection. Taking
all findings into account, we think LF-LAM has a role along with oth-
er tests among individuals with tuberculosis symptoms or with low
CD4 cell count. However, we had limited data and these findings
should be interpreted with caution.
The test does not require sputum collection and is not site-specif-
ic. Other favourable test characteristics include low-cost, rapidity
(< one hour), ease of use (does not require extensive sample prepa-
ration), and the fact that the test does not require electricity or spe-
cial instruments and equipment (WHO TTP 2014). As a simple point-
of-care test that does not depend upon sputum evaluation, LF-LAM
testing may be the only possible way to confirm a diagnosis when
a sputum sample cannot be produced.
Clinicians must consider the need for additional testing when inter-
preting negative LF-LAM results. The consequences of false-nega-
tive results are increased risk of morbidity and mortality, delayed
treatment initiation, and the continued risk of tuberculosis trans-
mission. The consequences of false-positive results are delayed al-
ternative diagnosis, likelihood of anxiety and morbidity caused by
additional testing, unnecessary treatment, and possible adverse
events; the possible stigma associated with a diagnosis of tubercu-
losis. As LF-LAM does not offer information about drug resistance, a
culture- or molecular-based diagnosis should be attempted to en-
able drug susceptibility testing to avoid that patients with uniden-
tified drug-resistant tuberculosis may be inappropriately treated
with a regimen appropriate only for drug-susceptible disease.
Ultimately, the use of LF-LAM in a clinical algorithm will not be
based on accuracy alone, but also on considerations of cost-effec-
tiveness, user perspectives and preferences, and the overall bene-
fits and harms of the test. This updated review contributed accura-
cy data for the WHO Guideline Development Group Meeting in May
2019. The updated WHO guidelines on the use of Alere LAM are ex-
pected later in 2019.
Implications for research
Future studies that evaluate the diagnostic accuracy of non-spu-
tum-based tests for tuberculosis, such as LF-LAM, in people living
with HIV should use a reference standard that includes at least
two different specimens (e.g. sputum, and urine), and in addi-
tion, for presumed extrapulmonary tuberculosis, appropriate spec-
imens from the suspected sites of involvement. Moreover, future
studies should include patients unable to expectorate sputum in
the analysis as these are most likely to benefit from the test. Char-
acteristics that possibly drive performance of the test in addition to
CD4 status, such as burden of disease, renal co-morbidities or oth-
er should be evaluated. More studies should evaluate LF-LAM accu-
racy in HIV-positive children, as currently there are very limited da-
ta available (Kroidl 2015; LaCourse 2018a; Nicol 2014). While some
studies enrolled unselected participants, our review suggests that
a large proportion were symptomatic, particularly in the inpatient
setting. Understanding whether there is value in using LF-LAM for
diagnosis of tuberculosis among HIV-positive people who do not re-
port any tuberculosis symptoms (particularly for those with CD4 <
100) remains unknown. Further studies among asymptomatic indi-
viduals are needed to better define the scope of recommendations
on the use of LF-LAM. The indication of increased sensitivity with
use of fresh urine and also morning urine needs further investiga-
tions, and studies in settings outside sub-Saharan Africa are lack-
ing. Further research on effective implementation of LF-LAM within
routine clinical practice is needed because the test can only influ-
ence clinical practice if the results are believed and acted upon.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Patient sampling Cross-sectional, prospective and consecutive enrolment
Patient characteristics and setting Presenting signs and symptoms: HIV-infected adults included irrespective
of symptoms. A positive WHO symptom screen was reported for 91% of par-
ticipants.
Age: mean 39 (SD10)
Sex, female: 64%
HIV infection: 100%
Median CD4 cell count per µL: 127 (IQR 35 to 256)
History of tuberculosis: 6%
Sample size: 469
Clinical setting: outpatient and inpatients
Country: Ghana
Tuberculosis incidence rate: 152 per 100,000
Number (proportion) of tuberculosis cases in the study: 55 (12%)
Index tests LF-LAM
Target condition and reference standard(s) Target condition: pulmonary tuberculosis
Reference standard: any of sputum mycobacterial culture (solid and liquid)
or nucleic acid amplification test; no extrapulmonary specimens tested
Flow and timing All patients were included in the analysis
Comparative  
Bjerrum 2015 
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Notes The study authors did not attempt sputum induction and excluded individ-
uals without some respiratory specimen available. There was no attempt to
identify extrapulmonary tuberculosis.
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? No    
    High Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify
the target condition?
No    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Yes    
    High Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Bjerrum 2015  (Continued)
 
 
Study characteristics
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Patient sampling Cross-sectional, prospective and consecutive enrolment
Patient characteristics and setting Presenting signs and symptoms: HIV-infected adults included irrespective
of symptoms. Proportion of participants that reported with tuberculosis
signs and symptoms symptomatic not stated.
Age: mean 33 (SD 9)
Sex, female: 49%
HIV infection: 100%
Median CD4 cell count per µL: 248 (IQR 107 to 379)
History of tuberculosis: 9%
Sample size: 320
Clinical setting: outpatient
Country: South Africa
Tuberculosis incidence rate: 567 per 100,000
Number (proportion) of tuberculosis cases in the study: 54 (17%)
Index tests LF-LAM
Target condition and reference standard(s) Target condition: pulmonary tuberculosis
Reference standard: mycobacterial culture of sputum (solid); no extrapul-
monary specimens tested
Flow and timing All patients were included in the analysis
Comparative  
Notes The study authors performed sputum induction for individuals who could
not expectorate, excluded individuals without some respiratory specimen
available. They did not attempt to identify extrapulmonary tuberculosis.
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? No    
    High Low
DOMAIN 2: Index Test All tests
Drain 2015a  (Continued)
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Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify
the target condition?
No    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Yes    
    High Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Drain 2015a  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective and consecutive enrolment
Patient characteristics and setting Presenting signs and symptoms: HIV-infected and HIV-uninfected adults sus-
pected of tuberculosis included if smear microscopy negative x 2; Presenting
with at least two of four tuberculosis-related symptoms: cough, fever, weight
loss, night sweats for at least two weeks and a Karnofsky performance score >50
Age: mean 37 (SD 9)
Sex, female: 49%
HIV infection: 93%
Median CD4 cell count per µL: 168 (IQR 89 to 256)
History of tuberculosis: not stated
Sample size: 90
Clinical setting: outpatient
Country: South Africa
Tuberculosis incidence rate: 567 per 100,000
Number (proportion) of tuberculosis cases in the study: 57 (63%)
Index tests LF-LAM
Target condition and reference standard(s) Target: pulmonary tuberculosis
Reference standard: any of sputum mycobacterial culture (solid and liquid) or
nucleic acid amplification test; no extrapulmonary specimens tested
Drain 2016 
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Flow and timing All patients were included in the analysis
Comparative  
Notes The study authors performed sputum induction for individuals who could not
expectorate. They excluded individuals without some respiratory specimen
available and did not attempt to identify extrapulmonary tuberculosis
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients
enrolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? No    
    High High
DOMAIN 2: Index Test All tests
Were the index test results interpreted without
knowledge of the results of the reference stan-
dard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly clas-
sify the target condition?
No    
Were the reference standard results interpret-
ed without knowledge of the results of the index
tests?
Yes    
    High Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index
test and reference standard?
Yes    
Did all patients receive the same reference stan-
dard?
Yes    
Were all patients included in the analysis? Yes    
    Low  
Drain 2016  (Continued)
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Study characteristics
Patient sampling Cross-sectional, prospective and consecutive enrolment
Patient characteristics and setting Presenting signs and symptoms: HIV-infected adults included irrespective
of symptoms. A positive WHO symptom screen was reported for 34% of
participants.
Age: median 35 (IQR 30-43)
Sex, female: 59%
HIV infection: 100%
Median CD4 cell count per µL: 278 (IQR 142 to 395)
History of tuberculosis: not stated
Sample size: 972
Clinical setting: outpatients
Country: Mozambique
Tuberculosis incidence rate: 551 per 100,000
Number (proportion) of tuberculosis cases in the study: 90 (9%)
Index tests LF-LAM
Target condition and reference standard(s) Target: pulmonary tuberculosis
Reference standard: nucleic acid amplification test; no extrapulmonary
specimens tested
Flow and timing All patients were included in the analysis
Comparative  
Notes The study authors did not attempt sputum induction and excluded in-
dividuals without some respiratory specimen available. They did not at-
tempt to identify extrapulmonary tuberculosis.
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? No    
    High Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Floridia 2017 
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    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
No    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Unclear    
    High Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Floridia 2017  (Continued)
 
 
Study characteristics
Patient sampling Cohort, prospective and consecutive enrolment with six months follow-up
Patient characteristics and setting Presenting signs and symptoms: HIV-infected adults included irrespective of
symptoms. A positive WHO symptom screen was reported for 53% of partici-
pants.
Age: median 39 (IQR 32-45)
Sex, female: 61%
HIV infection: 100%
Median CD4 cell count per µL: 111 (IQR 56 to 161)
History of tuberculosis: 30%
Sample size: 424
Clinical setting: outpatients
Country: South Africa
Tuberculosis incidence rate: 567 per 100,000
Number (proportion) of tuberculosis cases in the study: 40(9%)
Index tests LF-LAM
Target condition and reference standard(s) Target condition: pulmonary tuberculosis, extrapulmonary tuberculosis, my-
cobacteraemia
Reference standard: any of mycobacterial culture (liquid) or nucleic acid ampli-
fication test; extrapulmonary specimens tested for all
Flow and timing The study excluded 16 cases defined as ‘Clinical tuberculosis' from analysis.
Comparative  
Hanifa 2016 
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Notes Sputum and non-sputum samples were tested for mycobacteria for all par-
ticipants; The study authors performed sputum induction for individuals who
could not expectorate; The study had specimens collected for index test and ref-
erence standard tests greater than seven days apart.
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients
enrolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Unclear    
    Low Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted without
knowledge of the results of the reference stan-
dard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly clas-
sify the target condition?
Yes    
Were the reference standard results interpret-
ed without knowledge of the results of the index
tests?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index
test and reference standard?
No    
Did all patients receive the same reference stan-
dard?
Yes    
Were all patients included in the analysis? No    
    High  
Hanifa 2016  (Continued)
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Study characteristics
Patient sampling Cross-sectional, prospective and consecutive enrolment
Patient characteristics and setting Presenting signs and symptoms: HIV-infected adults suspected of tuberculosis; Pre-
senting with cough for more than 2 weeks or any cough and at least any of loss of
weight, night sweats, or fever
Age: median 35 (IQR:29-44)
Sex, female: 52%
HIV infection: 100%
Median CD4 cell count per µL: 109 (IQR 43 to 214)
History of tuberculosis: 25%
Sample size: 474 (275 included in analysis)
Clinical setting: outpatient and inpatients
Country: Kenya
Tuberculosis incidence rate: 319 per 100,000
Number (proportion) of tuberculosis cases in the study: 156 (57%)
Index tests LF-LAM
Target condition and reference standard(s) Target: pulmonary and extrapulmonary tuberculosis.
Reference standard: any of mycobacterial culture (solid and liquid) or nucleic acid
amplification test. Extrapulmonary specimens collected for participants without res-
piratory samples available
Flow and timing The study excluded participants with at least one sample with no result or contami-
nated result (culture) from analysis in the absence of a positive result.
Comparative  
Notes The study authors performed sputum induction for individuals who could not ex-
pectorate. They included individuals without respiratory specimen available and at-
tempted to identify extrapulmonary tuberculosis; Not all participants received the
same reference standard and not all participants were included in the analysis.
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of pa-
tients enrolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclu-
sions?
No    
    High Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted with-
out knowledge of the results of the refer-
ence standard?
Yes    
Huerga 2017 
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If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly
classify the target condition?
No    
Were the reference standard results inter-
preted without knowledge of the results of
the index tests?
Unclear    
    High Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between
index test and reference standard?
Yes    
Did all patients receive the same reference
standard?
No    
Were all patients included in the analysis? No    
    High  
Huerga 2017  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective and consecutive enrolment
Patient characteristics and setting Presenting signs and symptoms: HIV-infected and HIV-uninfected adults
(aged above 14 years) suspected of extrapulmonary tuberculosis.
Age: 43 (SD: 14.8)
Sex, female: 46%
HIV infection: 68%
Median CD4 cell count per µL: not stated
History of tuberculosis: 6%
Sample size: 99 (67 with HIV included)
Clinical setting: inpatients
Country: Kenya
Tuberculosis incidence rate: 319 per 100,000
Number (proportion) of tuberculosis cases in the study: 29 (33%)
Index tests LF-LAM
Target condition and reference standard(s) Target: extrapulmonary tuberculosis, any site
Reference standard: any of mycobacterial culture (solid and liquid) or
nucleic acid amplification test. No sputum specimens tested
Flow and timing All patients were included in the analysis
Juma 2017 
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Comparative  
Notes The study excluded participants with suspected pulmonary tuberculo-
sis and the reference standard was restricted to extrapulmonary speci-
mens
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? No    
    High Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    High High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
No    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
    High Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? No    
Were all patients included in the analysis? Yes    
    Low  
Juma 2017  (Continued)
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Study characteristics
Patient sampling Cross-sectional, prospective and consecutive enrolment
Patient characteristics and setting Presenting signs and symptoms: HIV-infected pregnant women attend-
ing antenatal care was included irrespective of symptoms. A positive WHO
symptom screen was reported for 19% of participants.
Other characteristics: pregnant women
Age: median 25 (IQR 22 to 30)
Sex, female: 100%
HIV infection: 100%
Median CD4 cell count per µL: 437 (IQR 342 to 565)
History of tuberculosis: 9%
Sample size: 266
Clinical setting: outpatient
Country: Kenya
Tuberculosis incidence rate: 319 per 100,000
Number (proportion) of tuberculosis cases in the study: 3 (1%)
Index tests LF-LAM
Target condition and reference standard(s) Target condition: pulmonary tuberculosis
Reference standard: expectorated sputum mycobacterial culture (liquid)
Flow and timing All patients were included in the analysis
Comparative  
Notes The study authors did not attempt sputum induction and excluded individ-
uals without some respiratory specimen available. There was no attempt to
identify extrapulmonary tuberculosis.
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? No    
    High Low
LaCourse 2016 
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DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify
the target condition?
No    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Yes    
    High Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
LaCourse 2016  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective and consecutive enrolment
Patient characteristics and setting Presenting signs and symptoms: HIV-infected adults included irrespective
of symptoms. A positive WHO symptom screen was reported for 91% of par-
ticipants
Age: median 36 (IQR 29-42)
Sex, female: 61%
HIV infection: 100%
Median CD4 cell count per µL: 149 (IQR 55 to 312)
History of tuberculosis: 6%
Sample size: 413
Clinical setting: inpatients
Country: South Africa
Tuberculosis incidence rate: 567 per 100,000
Number (proportion) of tuberculosis cases in the study: 139 (32.6%)
Index tests LF-LAM
Target condition and reference standard(s) Target: pulmonary tuberculosis, extrapulmonary tuberculosis, mycobacter-
aemia
Lawn 2017 
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Reference standard: any of mycobacterial culture (liquid) or nucleic acid
amplification test; extrapulmonary specimens tested for all
Flow and timing All patients were included in the analysis
Comparative  
Notes The study authors performed sputum induction for individuals who could
not expectorate. They included individuals without respiratory specimen
and attempted to identify extrapulmonary tuberculosis
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify
the target condition?
Yes    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? No    
Were all patients included in the analysis? Yes    
    Low  
Lawn 2017  (Continued)
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Study characteristics
Patient sampling Cross-sectional, prospective and consecutive enrolment
Patient characteristics and setting Presenting signs and symptoms: HIV-infected adults suspected of tuberculo-
sis; Presented with any of cough, fever, night sweats and weight loss
Age: median 33 (IQR 29 to 37)
Sex, female: 63%
HIV infection: 100%
Median CD4 cell count per µL: 152 (IQR 41 to 337)
History of tuberculosis: not stated
Sample size: 997
Clinical setting: inpatient and outpatient
Country: South Africa and Uganda
Tuberculosis incidence rate: 567 per 100,000 (South Africa); 201per 100,000
(Uganda)
Number (proportion) of tuberculosis cases in the study: 367 (37%)
Index tests LF-LAM
Target condition and reference standard(s) Target condition: pulmonary tuberculosis, mycobacteraemia
Reference standard: sputum mycobacterial culture (liquid and solid), my-
cobacterial blood cultures; extrapulmonary specimens tested for all
Flow and timing All patients were included in the analysis
Comparative  
Notes The study authors performed sputum induction for individuals who could not
expectorate. They excluded individuals without some respiratory specimen
available. They attempted to identify extrapulmonary tuberculosis
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients
enrolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? No    
    High Low
Nakiyingi 2014 
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DOMAIN 2: Index Test All tests
Were the index test results interpreted without
knowledge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classi-
fy the target condition?
Yes    
Were the reference standard results interpreted
without knowledge of the results of the index tests?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index
test and reference standard?
Yes    
Did all patients receive the same reference stan-
dard?
Yes    
Were all patients included in the analysis? Yes    
    Low  
Nakiyingi 2014  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective and consecutive enrolment
Patient characteristics and setting Presenting signs and symptoms: HIV-infected and HIV-uninfected adults suspected of
pericardial tuberculosis. Presented with pericardial effusion
Age: median 34 (IQR 29-42)
Sex, female: 38%
HIV infection: 74%
Median CD4 cell count per µL: 139 (IQR 81 to 249)
History of tuberculosis: not stated
Sample size: 102
Clinical setting: inpatients
Country: South Africa
Tuberculosis incidence rate: 567 per 100,000
Number (proportion) of tuberculosis cases in the study: 74 (49%)
Index tests LF-LAM
Target condition and reference standard(s) Target condition: extrapulmonary tuberculosis (pericardial tuberculosis) and pul-
monary tuberculosis
Pandie 2016 
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Reference standard: mycobacterial culture (liquid). There was no protocol to ensure a
minimum standard of sputum sampling and testing
Flow and timing Not all patients were included in the analysis
Comparative  
Notes The study authors excluded participants with disseminated tuberculosis if not having
pericardial effusion, and excluded patients with pulmonary tuberculosis if no sign of
pericardial effusion. Not all patients received the same reference standard. For some
patients sputum induction was attempted and sputum examined for mycobacteria.
Not all participants were included in the analysis and it is unclear who was excluded.
The true negative values reported conflicts and provides uncertainty about the speci-
ficity reported.
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of pa-
tients enrolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclu-
sions?
No    
    High Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted with-
out knowledge of the results of the refer-
ence standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly
classify the target condition?
No    
Were the reference standard results inter-
preted without knowledge of the results of
the index tests?
Yes    
    High High
DOMAIN 4: Flow and Timing
Was there an appropriate interval between
index test and reference standard?
Yes    
Pandie 2016  (Continued)
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Did all patients receive the same reference
standard?
No    
Were all patients included in the analysis? No    
    High  
Pandie 2016  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective and consecutive enrolment
Patient characteristics and setting Presenting signs and symptoms: HIV-infected adults suspected of tuberculosis;
Presenting with signs and symptoms suggestive of tuberculosis, but these not
specified
Age: median 35 (IQR 29 to 40)
Sex, female: 60%
HIV infection: 100%
Median CD4 cell count per µL: 90 (IQR 47 to 197)
History of tuberculosis: 35%
Sample size: 241
Clinical setting: inpatient
Country: South Africa
Tuberculosis incidence rate: 567 per 100,000
Number (proportion) of tuberculosis cases in the study: 116 (48%)
Index tests LF-LAM
Target condition and reference standard(s) Target condition: pulmonary tuberculosis and extrapulmonary tuberculosis
Reference standard: mycobacterial culture (liquid); there was no protocol to en-
sure a minimum standard of respiratory and extrapulmonary specimen testing
Flow and timing All patients were included in the analysis
Comparative  
Notes The study authors included all patients with symptoms of tuberculosis irrespec-
tive of their ability to produce sputum; clinicians chose the reference standard
rather than it being directed by the study protocol. The reference standard in-
cluded testing of pulmonary and extrapulmonary sites by mycobacterial cul-
ture.
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
Peter 2012a 
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DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients
enrolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted without
knowledge of the results of the reference stan-
dard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly clas-
sify the target condition?
No    
Were the reference standard results interpret-
ed without knowledge of the results of the index
tests?
Yes    
    High High
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index
test and reference standard?
Yes    
Did all patients receive the same reference stan-
dard?
No    
Were all patients included in the analysis? Yes    
    High  
Peter 2012a  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective and consecutive enrolment
Patient characteristics and setting Presenting signs and symptoms: HIV-infected adults suspected of tubercu-
losis; presenting with any of cough,night sweats, fever or weight loss
Age: median 36 (IQR 30 to 41)
Sex, female: 46%
Peter 2015 
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HIV infection: 100%
Median CD4 cell count per µL: 210 (IQR 103 to 375)
History of tuberculosis: 26%
Sample size: 569
Clinical setting: outpatient
Country: South Africa, Tanzania, Zambia
Tuberculosis incidence rate: 567 per 100,000 (South Africa); 269 per 100,000
(Tanzania); 361 per 100,000 (Zambia)
Number (proportion) of tuberculosis cases in the study: 181 (32%)
Index tests LF-LAM
Target condition and reference standard(s) Target condition: pulmonary tuberculosis
Reference standard: sputum mycobacterial (liquid) culture
Flow and timing All patients were included in the analysis
Comparative  
Notes The study authors excluded individuals unable to expectorate sputum and
did not attempt sputum induction. They did not attempt to identify extra-
pulmonary tuberculosis .
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? No    
    High Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Peter 2015  (Continued)
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Is the reference standards likely to correctly classify
the target condition?
No    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Yes    
    High Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Peter 2015  (Continued)
 
 
Study characteristics
Patient sampling Randomized controlled trial, consecutive prospective enrolment
Patient characteristics and setting Presenting signs and symptoms: HIV-infected adults suspected of tuberculosis; Pre-
senting with any of cough, night sweats, fever, or weight loss; or Illness that necessi-
tate admission
Age: median 37 (IQR 30 to 44)
Sex, female: 50%
HIV infection: 100%
Median CD4 cell count per µL: 81 (IQR 26 to 198)
History of tuberculosis: 27%
Sample size: 1172
Clinical setting: inpatient
Country: South Africa, Zimbabwe, Zambia
Tuberculosis incidence rate: 567 per 100,000 (South Africa); 221 per 100,000 (Zimbab-
we); 361 per 100,000 (Zambia)
Number (proportion) of tuberculosis cases in the study: 342 (29%)
Index tests LF-LAM
Target condition and reference standard(s) Target condition: pulmonary tuberculosis, extrapulmonary tuberculosis, mycobac-
teraemia
Reference standard: any of mycobacterial culture (solid and liquid) or nucleic acid
amplification test; extrapulmonary specimens collected for those participants where
treating clinicians found it indicated
Peter 2016 
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Flow and timing All patients were included in the analysis
Comparative  
Notes Health providers selected the sites for testing based on their own clinical suspicion.
High concern of applicability because of a lack of study directed extrapulmonary test-
ing. Not all participants received the same reference standard as tuberculosis diag-
nostics performed at the discretion of the clinician and varied across sites.
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of pa-
tients enrolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclu-
sions?
Yes    
    Low Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted with-
out knowledge of the results of the refer-
ence standard?
No    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly
classify the target condition?
No    
Were the reference standard results inter-
preted without knowledge of the results of
the index tests?
Yes    
    High High
DOMAIN 4: Flow and Timing
Was there an appropriate interval between
index test and reference standard?
Yes    
Did all patients receive the same reference
standard?
No    
Were all patients included in the analysis? Yes    
    High  
Peter 2016  (Continued)
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Study characteristics
Patient sampling Cohort, prospective and consecutive enrolment with six months follow-up
Patient characteristics and setting Presenting signs and symptoms: irrespective of symptoms. WHO tuberculosis symp-
tom screen positive in 33%. in overall population who could produce sputum signs
and symptoms suggestive of tuberculosis, but not specified
Age: median 34 (IQR 30-41)
Sex, female: 50%
HIV infection: 100%
Median CD4 cell count per µL: 270 (IQR 128 to 443)
History of tuberculosis: not stated
Sample size: 517
Clinical setting: outpatient and inpatients
Country: Myanmar
Tuberculosis incidence rate: 358 per 100.000
Number (proportion) of tuberculosis cases in the study: 54 (12%)
Index tests LF-LAM
Target condition and reference standard(s) Target condition: pulmonary tuberculosis
Reference standard: any of sputum mycobacterial culture (solid and liquid) or nu-
cleic acid amplification test; no extrapulmonary specimens tested. The study did
not report if they speciated mycobacteria isolates
Flow and timing The study had specimens collected for index and reference standard tests greater
than seven days apart.
Comparative  
Notes The study authors attempted sputum induction and excluded individuals without
some respiratory specimen available. They did not attempt to identify extrapul-
monary tuberculosis. The study did not report if they speciated mycobacteria iso-
lates.
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of pa-
tients enrolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Low
DOMAIN 2: Index Test All tests
Thit 2017 
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Were the index test results interpreted with-
out knowledge of the results of the reference
standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly
classify the target condition?
No    
Were the reference standard results interpret-
ed without knowledge of the results of the in-
dex tests?
Unclear    
    High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between in-
dex test and reference standard?
No    
Did all patients receive the same reference
standard?
Yes    
Were all patients included in the analysis? Yes    
    High  
Thit 2017  (Continued)
Abbreviations: LF-LAM: lateral flow urine lipoarabinomannan assay (Alere Determine™ TB lipoarabinomannan); IQR: interquartile range;
SD: standard deviation; WHO: World Health Organization
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Agha 2013 Index test not studied
Amoudy 1997 Index test not studied
Andrews 2014 Abstract
Balcha 2014 Did not use manufacturer's current recommended positivity threshold
Bisson 2016 Abstract
Blanc 2018 Abstract
Boehme 2005 Index test not studied
Boyles 2012 Index test not studied
Broughton 2017 Study protocol
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Study Reason for exclusion
Calligaro 2017 Insufficient data
Chan 2000 Index test not studied
Cho 1997 Index test not studied
Conesa-Botella 2007 Index test not studied
Cox 2015 Did not use manufacturer's current recommended positivity threshold
d'Elia 2015 Reference standard not satisfied
Daley 2009 Index test not studied
Deng 2011 Index test not studied
Dheda 2009 Index test not studied
Dheda 2010 Index test not studied
Drain 2014a Did not use manufacturer's current recommended positivity threshold
Drain 2014b Abstract
Drain 2015b Impact study (no diagnostic accuracy data)
Drain 2016a Did not use manufacturer’s current recommended positivity threshold
Drain 2017 Impact study (no diagnostic accuracy data)
Elsawy 2012 Index test not studied
Gina 2017 Reference standard not satisfied
Gounder 2011 Index test not studied
Grant 2016 Abstract
Gupta-Wright 2016a Not a diagnostic accuracy study
Gupta-Wright 2016b Study protocol, study completed
Gupta-Wright 2018b Abstract
Hamasur 2001 Index test not studied
Hanifa 2015 Index test not studied
Iskandar 2017 Paediatric population
Kashino 2008 Index test not studied
Kerkhoff 2014a Insufficient or duplicate data
Kerkhoff 2014b Insufficient or duplicate data
Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
65
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study Reason for exclusion
Kerkhoff 2017 Second reference (complementary data) to Lawn 2017
Koralnik 2017 Abstract
Koulchin 2007 Index test not studied
Kroidi 2014 Index test not studied
Kroidl 2015 Paediatric population
LaCourse 2018a Paediatric population
LaCourse 2018b Paediatric population
Lawn 2009a Index test not studied
Lawn 2012a Did not use manufacturer's current recommended positivity threshold
Lawn 2012b Insufficient or duplicate data
Lawn 2013a Insufficient or duplicate data
Lawn 2014 Abstract
Leopold 2017 Abstract
Love 2016 Abstract
Manabe 2014 Insufficient or duplicate data
Mathabire 2017 Abstract
Mukundan 2012 Index test not studied
Musarurwa 2018 Not a diagnostic accuracy study
Mutetwa 2009 Index test not studied
Nakiyingi 2015 Second reference (complementary data) to Nakiyingi 2014
Nakiyingi 2015a Second reference (complementary data) to Nakiyingi 2014
Nicol 2014 Paediatric population
Patel 2009 Index test not studied
Patel 2010 Index test not studied
Peter 2011 Insufficient or duplicate data
Peter 2012b Insufficient or duplicate data
Peter 2012c Insufficient or duplicate data
Peter 2013 Insufficient or duplicate data
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Study Reason for exclusion
Reddy 2018 Abstract
Reid 2015 Insufficient data
Reither 2009 Index test not studied
Sabur 2017 Reference standard not satisfied
Sada 1992 Index test not studied
Sahle 2017 Did not use manufacturer's current recommended positivity threshold
Savolainen 2013 Index test not studied
Schmidt 2011 Index test not studied
Shah 2009 Index test not studied
Shah 2010 Index test not studied
Shah 2013 Insufficient or duplicate data
Shah 2014 Insufficient or duplicate data
Singh 2011 Index test not studied
Sun 2013 Insufficient data
Suwanpimolkul 2017 Did not use manufacturer's current recommended positivity threshold
Tessema 2001 Index test not studied
Tessema 2002a Index test not studied
Tessema 2002b Index test not studied
Tlali 2014 Insufficient or duplicate data
Van Rie 2013 Insufficient or duplicate data
Wood 2012 Index test not studied
Zijenah 2016 Second reference (complementary data) to Peter 2016
 
 
D A T A
Presented below are all the data for all of the tests entered into the
review.
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Table Tests.   Data tables by test
Test No. of studies No. of partici-
pants
1 Symptomatic adults, all settings 8 3449
2 Symptomatic adults, inpatients 6 2253
3 Symptomatic adults, outpatients 4 1196
4 Symptomatic adults, CD4 > 200, all settings 3 738
5 Symptomatic adults, CD4 ≤ 200, all settings 4 1825
6 Symptomatic adults, CD4 ≤ 200, inpatients 2 1009
7 Symptomatic adults, CD4 ≤ 200, outpatients 1 249
8 Symptomatic adults, CD4 > 100, all settings 4 1519
9 Symptomatic adults, CD4 ≤ 100, all settings 5 1251
10 Symptomatic adults, CD4 ≤ 100, inpatients 3 746
11 Symptomatic adults, CD4 ≤ 100, outpatients 1 121
12 Symptomatic adults, CD4 101-200, all settings 4 586
13 Symptomatic adults, CD4 101-200, inpatients 2 275
14 Symptomatic adults, CD4 101-200, outpatients 1 128
17 Unselected adults, all settings 7 3365
18 Unselected adults, inpatients 3 537
19 Unselected adults, outpatients 6 2828
20 Unselected adults, CD4 > 200, all settings 1 156
21 Unselected adults, CD4 ≤ 200, all settings 2 706
22 Unselected adults, CD4 ≤ 200, inpatients 1 54
23 Unselected adults, CD4 ≤ 200, outpatients 2 652
24 Unselected adults, CD4 > 100, all settings 4 952
25 Unselected adults, CD4 ≤ 100, all settings 3 417
26 Unselected adults, CD4 ≤ 100, inpatients 2 200
27 Unselected adults, CD4 ≤ 100, outpatients 2 217
28 Unselected adults, CD4 101-200, all settings 1 103
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Test No. of studies No. of partici-
pants
29 Unselected adults, CD4 101-200, inpatients 1 9
30 Unselected adults, CD4 101-200, outpatients 1 94
 
 
Test 1.   Symptomatic adults, all settings.
 
 
Test 2.   Symptomatic adults, inpatients.
 
 
Test 3.   Symptomatic adults, outpatients.
 
 
Test 4.   Symptomatic adults, CD4 > 200, all settings.
 
 
Test 5.   Symptomatic adults, CD4 ≤ 200, all settings.
 
 
Test 6.   Symptomatic adults, CD4 ≤ 200, inpatients.
 
 
Test 7.   Symptomatic adults, CD4 ≤ 200, outpatients.
 
 
Test 8.   Symptomatic adults, CD4 > 100, all settings.
 
 
Test 9.   Symptomatic adults, CD4 ≤ 100, all settings.
 
 
Test 10.   Symptomatic adults, CD4 ≤ 100, inpatients.
 
 
Test 11.   Symptomatic adults, CD4 ≤ 100, outpatients.
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Test 12.   Symptomatic adults, CD4 101-200, all settings.
 
 
Test 13.   Symptomatic adults, CD4 101-200, inpatients.
 
 
Test 14.   Symptomatic adults, CD4 101-200, outpatients.
 
 
Test 17.   Unselected adults, all settings.
 
 
Test 18.   Unselected adults, inpatients.
 
 
Test 19.   Unselected adults, outpatients.
 
 
Test 20.   Unselected adults, CD4 > 200, all settings.
 
 
Test 21.   Unselected adults, CD4 ≤ 200, all settings.
 
 
Test 22.   Unselected adults, CD4 ≤ 200, inpatients.
 
 
Test 23.   Unselected adults, CD4 ≤ 200, outpatients.
 
 
Test 24.   Unselected adults, CD4 > 100, all settings.
 
 
Test 25.   Unselected adults, CD4 ≤ 100, all settings.
 
 
Test 26.   Unselected adults, CD4 ≤ 100, inpatients.
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Test 27.   Unselected adults, CD4 ≤ 100, outpatients.
 
 
Test 28.   Unselected adults, CD4 101-200, all settings.
 
 
Test 29.   Unselected adults, CD4 101-200, inpatients.
 
 
Test 30.   Unselected adults, CD4 101-200, outpatients.
 
 
A D D I T I O N A L   T A B L E S
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Study Participants (% symptom) Setting Median
CD4 cell
count per
µL (IQR)
TB preva-
lence %
(n/N)
Did the
study
avoid in-
appropri-
ate exclu-
sion?
Specimens collected High-
quality
reference
standarda
Unique study
characteristics
HIV-positive adults with signs and symptoms of TB
Drain 2016 Symptomatic:
Two of four TB-related symptoms
(cough, fever weight loss, night
sweat) for > 2 weeks; smear mi-
croscopy negative x 2
Outpa-
tient
168 (89 to
256)
63%
(57/90)
No Pulmonary samples No Adults (> 18
years); HIV posi-
tive (93.2%); tar-
geting a relative-
ly well outpa-
tient population;
Karnofsky perfor-
mance score > 50
Huerga
2017
Symptomatic:
Cough > 2 weeks or any cough and
one of weight loss, night sweats or
fever; severely ill; CD4< 200 or BMI
below 17
Outpa-
tients
(33%); In-
patients
(67%)
109 (43 to
214)
57%
(156/275)
No Pulmonary samples; urine
Xpert only for patients with-
out sputum available
No Adults (> 15
years); LAM-guid-
ed treatment; ex-
cluded many par-
ticipants from
analysisb
Juma 2017 Symptomatic:
Suggestive of extrapulmonary TB,
not specified
Inpatients Not stated 33%
(29/67)
No Extrapulmonary samples
only, no sputum samples
No Adults (> 14
years), HIV-pos-
itive (68%); ex-
cluded patients
with concomi-
tants active pul-
monary TB
Nakiyingi
2014
Symptomatic:
Any of cough, fever weight loss,
night sweat
Outpa-
tients
(45%); In-
patients
(55%)
152 (41 to
337)
37%
(367/997)
No Pulmonary samples; Blood
culture for all
Yes Adults (> 18
years); multisite;
large sample size.
Pandie
2016
Symptomatic:
Presence of a pericardial effusion
and suspected of pericardial TB
Inpatients 139
(81 to 249)
95%
(36/38)
No Extrapulmonary samples
(pericardial effusion); pul-
monary samples for some
No Adults (> 18
years); HIV-pos-
itive (74%); ex-
cluded partici-
pants from analy-
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sis affecting
specificityc
Peter
2012a
Symptomatic:
Any of cough, fever weight loss,
night sweat
Inpatients 90
(47 to 197)
48%
(116/241)
Yes Clinically relevant pul-
monary samples; clinical-
ly relevant extrapulmonary
samples. No study defined
algorithm.
No Adults (> 18
years); multi-
site; TB diagnos-
tic work-up was
not standardized
but up to clinical
judgements
Peter 2015 Symptomatic:
Any of cough, fever weight loss,
night sweat
Outpa-
tients
210
(103 to
375)
32%
(181/569)
No Pulmonary samples No Adults (> 18
years); multisite;
nested within a
randomized, par-
allel-arm trial.
Peter 2016 Symptomatic:
Any of cough, fever weight loss,
night sweat
Inpatients 81
(26 to 198)
29%
(342/1172)
Yes Pulmonary samples; clin-
ically relevant extrapul-
monary samples. No study
defined algorithm.
No Adults (> 18
years); multisite;
LAM arm of a ran-
domized con-
trolled trial.
HIV-positive adults irrespective of signs and symptoms of TB
Bjerrum
2015
Unselected:
91% symptomatic
Outpa-
tients
(85%); In-
patients
(15%)
127
(35 to 256)
12%
(55/469)
No Pulmonary samples No Adults (> 18
years); majority
symptomatic.
Drain
2015a
Unselected:
proportion symptomatic not stated
Outpa-
tient
248
(107 to
379)
17%
(54/320)
No Pulmonary samples No Adults (> 18
years)
Floridia
2017
Unselected:
34% symptomatic
Outpa-
tient
278
(142 to
395)
9%
(90/972)
No Pulmonary samples No Adults (> 15
years). LAM-guid-
ed treatment.
Hanifa
2016
Unselected:
53% symptomatic
Outpa-
tient
111
(56 to 161)
9%
(40/408)
Yes Pulmonary samples; blood
culture for all
Yes Adults (> 18
years); CD4 < 200;
reference stan-
dard included
any sample taken
Table 1.   Summary characteristics of included studies  (Continued)
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within six months
from enrolment.
LaCourse
2016
Unselected:
19% symptomatic
Outpa-
tient
437
(342 to
565)
1%
(3/266)
No Pulmonary samples No Pregnant women
(> 16 years) at-
tending ANC;
healthy popula-
tion; one person
with CD4< 400;
Few TB cases (n =
3).
Lawn 2017 Unselected:
91% symptomatic
Inpatients 149
(55-312)
33%
(139/413)
Yes Pulmonary samples; Blood
culture for all; Clinically rel-
evant extrapulmonary sam-
ples
Yes Adults (> 18
years). Included
many samples
from different
sites
Thit 2017 Unselected:
33% symptomatic
Outpa-
tients
(90%); In-
patients
(10%)
270
(128 to
443)
10%
(54/517)
Yes Pulmonary samples No Conducted in
Myanmar. Adults
(median age 34).
Reference stan-
dard included
samples taken
within six months
from enrolment.
Table 1.   Summary characteristics of included studies  (Continued)
Abbreviations: LF-LAM: lateral flow urine lipoarabinomannan assay (Alere Determine™ TB lipoarabinomannan assay); ANC: antenatal clinic; BMI: body mass index; IQR: in-
terquartile range; TB: tuberculosis; Xpert: Xpert MTB/RIF
aFor a microbiological reference standard, we considered a higher quality reference standard to be one in which two or more specimen types were evaluated for TB diagnosis
in all participants as part of a defined standardized study algorithm.
bHuerga 2017 excluded participants from analysis if missing Xpert results or culture contaminated for any of the samples in the absence of a positive result; overall samples size
474 (156 with TB); 275 included in analysis (156 with TB).
cPandie 2016 excluded a large number of non-TB participants from analysis; Overall samples size 102 (36 with TB); 38 included for analysis (36 TB cases).
 
 
Symptomatic participants Unselected participantsType of analy-
sis
Studies (total
participants)
Partic-
ipants
with TB
(%)
Pooled sensitivi-
ty (95% CrI)
Pooled specifici-
ty (95% CrI)
Studies (total
participants)
Partic-
ipants
with TB
(%)
Pooled sensitivi-
ty (95% CrI)
Pooled specifici-
ty (95% CrI)
Table 2.   LF-LAM pooled sensitivity and specificity for TB diagnosis, by study population  (Continued)
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Overall accura-
cy
8 studies
(3449)
1277
(37%)
42%
(31% to 55%)
91%
(85% to 95%)
7 studies
(3365)
432
(13%)
35%
(22% to 50%)
95%
(89% to 98%)
By setting
Inpatient 6 studies
(2253)
868
(39%)
52%
(40% to 64%)
87%
(78% to 93%)
3 studies
(537)
159
(30%)
62%
(41% to 83%)
84%
(48% to 96%)
Outpatient 4 studies
(1196)
409
(34%)
29%
(17% to 47%)
96%
(91% to 99%)
6 studies
(2828)
273
(10%)
31%
(18% to 47%)
95%
(87% to 99%)
By CD4 cell
CD4 > 200 3 studies
(738)
163
(22%)
16%
(8% to 31%)
94%
(81% to 97%)
1 studya
(156)
11
(7%)
Not applicable Not applicable
CD4 ≤ 200 4 studies
(1825)
722
(40%)
45%
(31% to 61%)
89%
(77% to 94%)
2 studies
(706)
82
(12%)
26%
(9% to 56%)
96%
(87% to 98%)
CD4 > 100 4 studies
(1519)
425
(28%)
17%
(10% to 27%)
95%
(89% to 98%)
4 studies
(952)
115
(12%)
20%
(10% to 35%)
98%
(95% to 99%)
CD4 ≤ 100 4 studies
(1239)
512
(41%)
54%
(38% to 69%)
88%
(77% to 94%)
3 studies
(417)
130
(31%)
47%
(40% to 64%)
90%
(77% to 96%)
CD4 101-199 4 studies
(586)
210
(36%)
24%
(14% to 38%)
90%
(77 to 96)
1 study
(103)b
13
(13%)
Not applicable Not applicable
By CD4 and setting
CD4 ≤ 200
inpatients
2 studies
(1009)
348
(34%)
54%
(34% to 73%)
80%
(58% to 91%)
1 studyc
(54)
14
(26%)
Not applicable Not applicable
CD4 ≤ 100
inpatients
2 studies
(734)
270
(37%)
61%
(40% to 78%)
81%
(61% to 91%)
2 studies
(200)
84
(42%)
57%
(33% to 79%)
90%
(69% to 97%)
Table 2.   LF-LAM pooled sensitivity and specificity for TB diagnosis, by study population  (Continued)
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CD4 101-199
inpatients
2 studies
(275)
78
(28%)
32%
(16% to 57%)
81%
(55% to 92%)
1 studyd
(9)
4
(44%)
Not applicable Not applicable
CD4 ≤ 200
outpatients
1 studyf
(249)
97
(39%)
Not applicable Not applicable 2 studies
(652)
68
(10%)
21%
(8% to 48%)
96%
(89% to 99%)
CD4 ≤ 100
outpatients
1 studyg
(121)
48
(40%)
Not applicable Not applicable 2 studies
(217)
46
(21%)
40%
(20 to 64)
87%
(68 to 94)
CD4 101-199
outpatients
1 studyh
(128)
51
(40%)
Not applicable Not applicable 1 studye
(94)
9
(10%)
Not applicable Not applicable
Table 2.   LF-LAM pooled sensitivity and specificity for TB diagnosis, by study population  (Continued)
Abbreviations: LF-LAM: lateral flow urine lipoarabinomannan assay (Alere Determine™ TB lipoarabinomannan assay); Crl: credible interval; TB: tuberculosis.
aBjerrum 2015, Sensitivity 27% (6% to 61%); Specificity 99% (96% to 100%); bBjerrum 2015, Sensitivity 38% (14% to 68%); Specificity 99% (94% to 100%); cBjerrum 2015, Sensitivity
64% (35% to 87%); Specificity 82% (67% to 93%); dBjerrum 2015, Sensitivity 75% (19% to 99%); Specificity 100% (48% to 100%); eBjerrum 2015, Sensitivity 22% (3% to 60%);
Specificity 99% (94% to 100%); fPeter 2015, Sensitivity 24% (16% to 33%); Specificity 94% (89% to 97%); gPeter 2015, Sensitivity 30% (18% to 46%); Specificity 93% (85% to 98%);
hPeter 2015, Sensitivity 18% (8% to 31%); Specificity 95% (87% to 99%).
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Symptomatic participants Unselected participantsType of analysis
Studies
partici-
pants
Pooled sen-
sitivity (95%
CrI)
Pooled
specificity
(95% CrI)
Studies
partici-
pants
Pooled
sensitivity
(95% CrI)
Pooled
specificity
(95% CrI)
Including studies at low risk of patient se-
lection bias
2 studies
1413
48%
(29% to 67%)
82%
(61% to 92%)
3 studies
1338
39%
(17% to
66%)
93%
(69% to
98%)
Including studies at low risk of reference
standard bias
1 study
997
Insufficient
data
Insufficient
data
2 studies
821
24%
(8% to
53%)
99%
(95% to
99%)
Including studies that used only fresh spec-
imens
4 studies
2511
52%
(38% to 68%)
91%
(82% to 95%)
5 studies
2544
41%
(26% to
56%)
93%
(82% to
97%)
Re-classificiation of Bjerrum 2015; Lawn
2017 as studies among symptomatic par-
ticipant (> 80% participants symptomatic)
10 studies
4331
42%
(33% to 52%)
93%
(88% to 96%)
5 studies
2483
31%
(16% to
50%)
94%
(84% to
98%)
Table 3.   Sensitivity analyses, LF-LAM  (Continued)
Abbreviations: LF-LAM: lateral flow urine lipoarabinomannan assay (Alere Determine™ TB lipoarabinomannan assay); Crl: Credible In-
terval
 
 
Symptomatic participants Unselected participantsType of
analysis
Studies (total
participants)
Pooled sensitivi-
ty (95% CrI)
Pooled specifici-
ty (95% CrI)
Studies (total
participants)
Pooled sensi-
tivity (95% CrI)
Pooled speci-
ficity (95% CrI)
Overall ac-
curacy
5 studies (2313) 45% (29% to 63%) 92% (80% to 97%) 3 studiesa
(1055 )
30% (20% to
43%)
94% (86% to
97%)
By setting
Inpatient 4 studies (1299) 53% (38% to 70%) 90 % (73% to
96%)
Insufficient data
Outpatient Insufficient data Insufficient data
Table 4.   Original Alere LAM review, main findings  (Continued)
Abbreviations: LF-LAM: lateral flow urine lipoarabinomannan assay (Alere Determine™ TB lipoarabinomannan assay); Crl: credible in-
terval
Main findings from the original review on LF-LAM accuracy (Shah 2016).
aReported at grade 1 on the previous reference scale card with five bands that is outdated and no longer the recommended positivity
threshold.
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A P P E N D I C E S
Appendix 1. Alere Determine TB LAM Ag test
Figure 10.
 
Figure 10.   (A) AlereTM TB LAM Ag test. To the sample pad (white pad marked by the arrow symbols) 60 µL of urine is
applied and visualized bands are read 25 minutes later. (B) Updated Reference Scale Card accompanying test strips
to ‘grade' the test result and Alere positivity. Copyright © [2019] [Abbott Inc]: reproduced with permission.
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Appendix 2. Reference card grading of Alere Determine TB LAM Ag test
Figure 11.
 
Figure 11.   Reference card grading of Alere Determine™ TB LAM. Comparison of the current reference card (top) with
the prior reference card (bottom). Copyright © [2019] [Abbott Inc]: reproduced with permission.
 
Appendix 3. Minimum specifications for a point-of-care TB diagnostic test
 
Test specification Minimum required value
Medical decision Treatment initiation
Sensitivity: adults
(for pulmonary tuberculosis
only;
regardless of HIV status)
Pulmonary tuberculosis
• 95% for smear positive, culture positive• 60% to 80% for smear negative, culture positive
(detection of extrapulmonary tuberculosis being a preferred but not minimal requirement)
Sensitivity: children
(including extrapulmonary tu-
berculosis;
regardless of HIV status)
• 80% compared to culture of any specimen and• 60% of probable tuberculosis (noting problem of lack of a gold standard)
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Specificity: adults • 95% compared to culture
Specificity: children • 90% for culture-negative probable tuberculosis (noting problem of lack of a gold standard)• 95% compared to culture
Time to results 3 hours maximum (patient must receive results the same day)
(desirable would be < 15 minutes)
Throughput 20 tests/day minimum, by one laboratory technician
Specimen type Adults: urine, oral, breath, venous blood, sputum
(desired: non sputum-based sample type and use of finger prick
instead of venous blood)
Children: urine, oral, capillary blood (finger or heel prick)
Sample preparation • 3 steps maximum• Safe: biosafety level 1• Ability to use approximate volumes (that is, no need for precise pipetting)• Preparation that is not highly time sensitive
Number of samples 1 sample per test
Readout • Easy-to-read, unambiguous, simple "yes", "no", or "invalid" answer• Readable for at least one hour
Waste disposal • Simple burning or sharps disposal; no glass component• Environmentally acceptable disposal
Controls • Positive control included in test kit• Quality control simpler and easier than with sputum smear microscopy
Reagents • All reagents in self-contained kit• Kit contains sample collection device and water (if needed)
Storage/stability required • Shelf life of 24 months, including reagents• Stable at 30°C, and at higher temperatures for shorter time periods• Stable in high humidity environments
Instrumentation • If instrument needed, no maintenance required• Instrument works in tropical conditions• Acceptable replacement cost• Fits in backpack• Shock resistant
Power requirement Can work on battery
Training
Cost
• 1 day maximum training time• Can be performed by any health worker
< USD 10 per test after scale-up
  (Continued)
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Copyright © Batz 2011; reproduced with permission.
Abbreviations: USD, United States Dollar.
Appendix 4. Detailed search strategies
MEDLINE (PubMed)
 
Search  
#9 Search (#3) AND (#7) AND #8)
#8 Search test OR assay OR antigen OR Ag OR lateral flow assay*OR urine antigen OR point of care
Field: Title/Abstract
#7 Search (#4) OR #5) OR #6
#6 Search LAM; Field: Title/Abstract
#5 Search "lipoarabinomannan" [Supplementary Concept]
#4 Search lipoarabinomannan ; Field: Title/Abstract
#3 Search (#1) OR #2)
#2 Search tuberculosis Or TB Field: Title/Abstract
#1 Search ("Tuberculosis"[Mesh]) OR "Mycobacterium tuberculosis"[Mesh]
 
 
Embase 1947-Present, updated daily
Search strategy:
--------------------------------------------------------------------------------
1 tuberculosis.mp. or tuberculosis/ or Mycobacterium tuberculosis/ (115438)
2 limit 1 to yr="2014 -Current" (8833)
3 lipoarabinomannan.mp. or lipoarabinomannan/ (775)
4 LAM.mp. (4928)
5 limit 4 to yr="2014 -Current" (500)
6 3 or 5 (1252)
7 2 and 6 (79)
8 (test or assay or antigen or Ag or lateral flow assay* or urine antigen or point of care).mp. [mp=title, abstract, subject headings, heading
word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (2733052)
9 limit 8 to yr="2014 -Current" (223771)
10 7 and 9 (46)
Cochrane Central Register of Controlled Trials : Issue 4 of 12, April 2018
ID Search
#1 tuberculosis:ti,ab,kw (Word variations have been searched)
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#2 TB:ti, ab, kw
#3 MeSH descriptor: [Mycobacterium tuberculosis] explode all trees
#4 MeSH descriptor: [Tuberculosis] explode all trees
#5 #1 or #2 or #3 or #4
#6 LAM:ti,ab,kw
#7 lipoarabinomannan:ti,ab,kw
#8 #6 or #7
#9 #5 and #8
Web of Science Core Collection - Indexes: SCI-EXPANDED, CPCI-S, Biosis previews
TOPIC: (tuberculosis OR TB OR mycobacterium) AND TOPIC: (lipoarabinomannan OR LAM) AND TOPIC: (test OR assay OR antigen OR Ag
OR lateral flow assay* OR urine antigen OR point of care)
SCOPUS
( TITLE-ABS-KEY ( tuberculosis OR TB) AND TITLE-ABS-KEY (lipoarabinomannan OR LAM) AND ( test OR diagnos* OR urine OR assay )
CIDG Specialized Register, LILACS, Proquest dissertations, Current Controlled trials, WHO trials register
Tuberculosis AND ( lipoarabinomannan OR LAM )
Appendix 5. Data collection form
 
LF-LAM- Lateral flow urine lipoarabinomannan assay for diagnosing active tuberculosis in people living with HIV
Data form
I. STUDY IDENTIFICATION
1 First author  
2 Corresponding author and email  
3 Title of study  
4 Year of publication  
5 Year of study start  
6 Language if other than English  
II. STUDY DETAILS
7 Population 1.Adults (15 years of age)
2.Children and adolescents
3.Both adults, children and adolescents
4.Other
If other, describe
8 In which country or countries was the study conducted? List all countries:
9 Country World Bank Classification (income) (World Bank
2018)
1.Low income
2.Lower-middle income
3.Upper-middle-income
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4.High income
7. Other combination
9.Unknown/Not reported
If other, describe:
10 Country WHO classification for high TB burden country
(WHO Global Tuberculosis Report 2018)
1.Yes, part of the High TB/HIV burden list
2.No, not part of the High TB/HIV burden list
11 Study design 1.Randomized controlled trial
2.Cross-sectional
3.Cohort
7.Other, specify
9.Could not tell
If other, describe:
12 Was a case-control design avoided? 1.Yes
2.No
9.Unclear
III. PATIENT SELECTION
13 What was the manner of participant selection into the
study?
1.Consecutive
2.Random
3.Convenience
7.Other, specify
9.Unknown/Not Reported/Unclear
If other, describe:
14 Direction of study data collection 1.Prospective
2.Retrospective
9.Unknown/Not reported
15 Please select the statement that best describes the selec-
tion of participants into the study.
1.HIV-positive participants with signs or symp-
toms suggestive of active tuberculosis were test-
ed using LF-LAM. Please provide study definition
of ‘signs and symptoms’:
2.A preAlered target population of HIV-posi-
tive individuals, irrespective of signs and symp-
toms of tuberculosis, were tested using LF-LAM.
Please specify target population:
3.Both 1 and 2
4.Neither 1 nor 2.
This is what was done:
16 Sample size 1._____
9.Unknown/Not reported
17 Did the study avoid inappropriate exclusions? 1.Yes
2.No
9.Unknown/Not reported/Unclear
17a Could the selection of patients have introduced bias? 1.High risk
2.Low risk
9.Unclear risk
18 NOTES ON PATIENT SELECTION  
IV. PATIENT CHARACTERISTICS AND SETTING
  (Continued)
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19 Presenting signs and symptoms List
20 Age (years) __________
If age is reported in median indicate IQR
If age is reported in mean indicate SD
21 Age of all study participants, Range Upper
Lower
22 HIV infection (%)  
23 Participants included of female sex (%)  
24 CD4 _________
If CD4 is reported in median indicate IQR
If CD4 is reported in mean indicate SD
25 Number (percent) of tuberculosis cases in the study (%):  
26 What was the target condition? 1.Pulmonary tuberculosis
2.Extra pulmonary tuberculosis
3.Mycobacteraemia
4.Both 1 and 2
5.Any of 1,2,3
7.Other, specify
27 Did the study include patients with prior tuberculosis histo-
ry?
1.Yes
2.No
9.Unknown/Not reported
If yes, what is the % _____
Specify the numerator/denominator _____/
_____
28 What was the clinical setting of the study? 1.Outpatient
2.Inpatient
3.Both out-patient and in-patient
7.Other, describe:
9.Unknown/Not reported
29 How would you describe the health facility where the study
took place?
1.Primary care clinic, stand alone
2.Primary care clinic, connected to a referral
hospital
3.Referral hospital
7.Other, describe:
9.Unknown/Not reported
30 Are there concerns that the included patients and setting
do not match the review question?
1.High concern
2.Low concern
9.Unclear concern
31 NOTES ON CHARACTERISTICS  
V. INDEX TEST
32 Was a LF-LAM threshold used to define positivity that was
pre-specified in the primary analysis?
1.Yes, Grade 1/5
2.Yes, Grade 2/5
3.Yes, Grade 1/4
  (Continued)
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4.Yes, Grade 2/4
5.No
7.Other, specify:
33 What LF-LAM threshold was used to define positivity for da-
ta extraction?
1.Grade 2/5
2.Grade 1/4
7. Other, specify
34 Are their concerns about index test conduct or interpreta-
tion differing from review question?
1.High concern
2.Low concern
9.Unclear concern
35 Was LF-LAM performed on fresh or stored urine? 1.Fresh
2.Stored, specify type of storage (e.g. frozen)
3.Both fresh and stored
9.Unknown/Not reported
36 Was LF-LAM result interpreted without knowledge of the re-
sult of the reference standard result?
1.Yes
2.No
9.Unknown/Not reported/Unclear
37 Were there any LF-LAM results that were invalid (no bar in
control window)?
1.Yes
a.Specify number of invalid tests: _____
b.Were invalid tests repeated (yes/no): _____
2.No
9. Unknown/Not reported
38 Could the conduct or interpretation of the index test have
introduced bias?
1.High risk
2.Low risk
9.Unclear risk
39 NOTES ON INDEX TEST  
VI. REFERENCE STANDARD
40 For the diagnosis of pulmonary tuberculosis, what refer-
ence standard was used to identify tuberculosis and not tu-
berculosis?
1.Sputum: solid culture
2.Sputum: liquid culture
3.Sputum: both solid and liquid culture
4.Nucleic acid amplification test, specify
5.Any of culture or nucleic amplification test,
specify
7.Other, specify
41 Was sputum induction performed for individuals unable to
produce expectorated sputum?
1.Yes
Specify N/% requiring sputum induction ____
2.No
42 Were patients without sputum specimens (for example, no
expectorated, no induced sputum) included in this study?
1.Yes
Specify N/% included without sputum ____
2.No
Specify N/% excluded due to lack of spu-
tum____
43 Were non-pulmonary specimens evaluated to allow diag-
nosis of extrapulmonary tuberculosis?
1.All participants received testing of non-pul-
monary specimens, please specify sites/fluids:
2.Some participants received testing of non-
pulmonary specimens, please specify which pa-
tients were tested, and sites/fluids:
  (Continued)
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3.Extrapulmonary tuberculosis was not evaluat-
ed
7.Other, please specify:
44 For the diagnosis of extrapulmonary tuberculosis, what
tests were used to identify tuberculosis and not tuberculo-
sis (circle all that apply)?
1.Solid culture
2.Liquid culture
3.Both solid and liquid culture
4.Nucleic acid amplification test, specify
7.Other, specify: __________________________
8.Not applicable, extrapulmonary tuberculosis
was not evaluated
45 Did the study speciate mycobacteria isolated in culture? 1.Yes
2.No
9.Unknown/Not reported
46 Was the reference standard likely to correctly classify the
target condition
1.Yes
2.No
9. Unclear
47 Was the reference standard result interpreted without
knowledge of the result of LF-LAM?
1.Yes
2.No
9.Unclear
48 How many sputum specimens were obtained in order to
detect pulmonary tuberculosis?
1. Single
2. Multiple
8.Not applicable
49 How many specimens from fluid (sites) other than sputum
were obtained to detect extrapulmonary tuberculosis?
1. Single
2. Multiple
8.Not applicable
50 Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
1.High risk
2.Low risk
9.Unclear risk
51 Are there concerns that the target condition as defined by
the reference standard does not match the question?
1.High concern
2.Low concern
9.Unclear concern
52 NOTES ON REFERENCE STANDARD  
VII. FLOW AND TIMING
53 Was there appropriate interval between index test and ref-
erence standard
1.Yes, specimens collected at the same time.
2.No, specimens collected greater than 7 days
apart
9.Unclear
54 Did all patients receive a reference standard? 1.Yes
2.No
9.Unclear
55 Did all patients receive the same reference standard? 1.Yes
2.No (answer no if clinicians chose sample types,
or other differences in reference standards be-
tween patients)
9.Unclear
  (Continued)
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56 Were all participants included in the analysis? 1.Yes
2.No
9.Unclear
57 Could the patient flow have introduced bias? 1.High risk
2.Low risk
9.Unclear risk
58 NOTES ON FLOW AND TIMING  
  (Continued)
 
Abbreviations: IQR, interquartile range; SD, standard deviation.
VIII. TABLES: Tuberculosis detection against a microbiological reference standard
Tuberculosis is defined as positive culture or NAAT from sputum or any body fluid or site.
Not Tuberculosis is defined as negative cultures or NAATs from sputum or any body fluid or site.
(Table example; provide additional tables for each of the applicable questions)
 
  Tuberculosis Not tuberculosis Total
Positive      
Negative      
LAM result
Total      
  (Continued)
 
Provide additional tables for each of the questions:
What is the diagnostic accuracy of LF-LAM for the diagnosis of tuberculosis in all HIV-positive adults with advanced HIV disease and
signs and symptoms of tuberculosis?
a. in inpatient setting CD4 ≤ 200
b. in outpatient setting CD4 ≤ 200
c. in all settings CD4 ≤ 200
d. in all settings CD4 > 200
e. in inpatient setting CD4 ≤ 100
f. in outpatient setting CD4 ≤ 100
g. in all settings CD4 ≤ 100
h. in all settings CD4 > 100
i. in inpatients settings CD4 101 to 200
j. in outpatient settings CD4 101 to 200
k. in all settings CD4 101 to 199
What is the diagnostic accuracy of LF-LAM for the diagnosis of tuberculosis in adults with advanced HIV disease irrespective of signs
and symptoms of tuberculosis?
a. in all settings CD4 > 200
b. in all settings CD4 > 100
c. in inpatients settings CD4 101 to 200
d. in outpatient settings CD4 101 to 200
e. in all settings CD4 101 to 199
Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
87
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Appendix 6. QUADAS-2
Domain 1: patient selection
Risk of bias: could the selection of patients have introduced bias?
Signaling question 1: Was a consecutive or random sample of patients enrolled?
We answered ‘yes' if the study enrolled a consecutive or random sample of eligible participants; ‘no' if the study selected participants by
convenience; and ‘unclear' if the study did not report the manner of participant selection or we could not tell.
Signaling question 2: Was a case-control design avoided?
We answered ‘yes' to all included studies given that we are excluding case-control study designs.
Signaling question 3: Did the study avoid inappropriate exclusion?
We answered ‘yes' to studies which included all HIV-positive participants and participants who were unable to produce sputum (expecto-
rated or induced). We answered ‘no' if studies excluded participants who could not produce sputum (i.e. there were no attempts at sputum
induction or patients could not produce sputum despite sputum induction and were excluded). We also answered ‘no' if studies excluded
patients presumed to have extrapulmonary tuberculosis. We scored ‘unclear' if we could not tell.
Applicability: Are there concerns that the included patients and setting do not match the review question?
We were interested in how LF-LAM performs in patients whose urine specimens were evaluated as they would be in routine practice. We
expected to judge ‘low concern’ for most studies since we planned to determine test accuracy both for patients with signs and symptoms
of tuberculosis and patients investigated for tuberculosis irrespective of signs and symptoms for tuberculosis.
For LF-LAM used as a tuberculosis diagnostic test among patients with signs and symptoms of tuberculosis, we judged ‘high concern'
if the study participants did not resemble people with presumed HIV/tuberculosis; ‘low concern' if the study population did resemble a
population with presumed HIV/tuberculosis, and ‘unclear concern', if we could not tell.
For LF-LAM used as a tuberculosis diagnostic test among patients that were investigated for tuberculosis irrespective of signs and symp-
toms of tuberculosis, we judged ‘low concern' for studies in which the LF-LAM was performed uniformly within the predetermined study
target populations of HIV-infected individuals, ‘high concern' if LF-LAM was not performed uniformly within the predetermined study tar-
get populations of HIV-infected individuals, and ‘unclear concern' if we could not tell. We judged ‘high concern' if the study participants
did not resemble people with presumed HIV/tuberculosis coinfection.
Domain 2: index test
Risk of bias: could the conduct or interpretation of the index test have introduced bias?
Signaling question 1: were the index test results interpreted without knowledge of the results of the reference standard?
We answered ‘yes' if the study interpreted the result of LF-LAM blinded to the result of the reference standard; we answered ‘no' if the
study did not interpret the result of LF-LAM blinded to the result of the reference standard. We answered ‘yes' for studies in which LF-LAM
was performed on fresh specimens, since reference standard results would be unavailable at the time of test interpretation. We answered
‘unclear' if stored specimens were tested and we could not tell if the index test results were interpreted without knowledge of the reference
standard results.
Signaling question 2: if a LF-LAM threshold was used to define positivity, was it prespecified?
We answered ‘yes' if the threshold was prespecified in the study or by the authors, ‘no' if the threshold was not prespecified, and ‘unclear'
if we could not determine if the threshold was prespecified or not.
Applicability: are there concerns that the index test, its conduct, or its interpretation diOer from the review question?
If index test methods vary from those specified in the review question, concerns about applicability may exist. We judged ‘high concern'
if the test procedure was inconsistent with the manufacturer recommendations, ‘low concern' if the test procedure was consistent with
the manufacturer recommendations, and ‘unclear concern' if we could not tell. In cases where the primary study defined grade 1 of 5 as
the positivity threshold, but where we were able to extract data at the manufacturer’s currently recommended positivity threshold, we
judged ‘low concern’ for applicability.
Domain 3: reference standard
Risk of bias: could the reference standard, its conduct, or its interpretation have introduced bias?
Signaling question 1: is the reference standard likely to correctly classify the target condition?
HIV-infected tuberculosis patients may have pulmonary tuberculosis, extrapulmonary tuberculosis, or both pulmonary and extrapul-
monary tuberculosis. A microbiological reference standard, primarily culture, is considered the gold standard for tuberculosis. Owing to
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the difficulties in diagnosing HIV-associated tuberculosis, it is recommended that multiple cultures from sputum and other specimens be
evaluated.
We answered ‘yes' when appropriate specimens were obtained for the diagnosis of HIV-associated tuberculosis. For presumed pulmonary
tuberculosis, sputum specimens should be obtained for culture, NAAT, or both culture and NAAT. If the patient cannot produce sputum,
induced sputum should be performed. For presumed extrapulmonary tuberculosis, specimens should be consistent with Standard 4 of
the International Standards for Tuberculosis Care which states: "For all patients, including children, suspected of having extrapulmonary
tuberculosis, appropriate specimens from the suspected sites of involvement should be obtained for microbiological and histological
examination" (TB CARE I 2014). We answered yes if multiple specimens were collected from different sites for extrapulmonary tuberculosis.
An Xpert® MTB/RIF test is recommended as the preferred initial microbiological test for suspected tuberculosis meningitis because of the
need for a rapid diagnosis". We also answered ‘yes' if studies followed a standardized approach of collecting appropriate specimens from
"suspected sites of involvement", for example, blood or lymph nodes on all patients.
We answered ‘no' when the reference standard was restricted to sputum specimens or the reference standard was restricted to extrapul-
monary specimens (for example, urine, blood, etc.). We also answered ‘no' if a consistent approach was not followed for all patients (for
example, some but not all patients with presumed tuberculosis lymphadenitis receive lymph node tissue sampling). We answered ‘un-
clear' if we could not tell.
Signaling question 2: were the reference standard results interpreted without knowledge of the results of the index test?
We answered ‘yes' if the study interpreted the result of the reference standard blinded to the result of LF-LAM, or if the reference standard
result was reported on an automated instrument; ‘no' if the study did not interpret the result of the reference standard blinded to the
result of LF-LAM, and ‘unclear' if we could not tell.
Applicability: are there concerns that the target condition as defined by the reference standard does not match the question?
In general, we thought there was low concern for almost included studies based on the current definitions of the reference standard. We
judged ‘high concern' if included studies did not speciate mycobacteria isolated in culture, ‘low concern' if speciation was performed,
and ‘unclear' if we could not tell. We also judged high concern if there was no protocol to ensure a minimum standard of testing with a
reference standard.
Domain 4: Flow and timing
Risk of bias: could the patient flow have introduced bias?
Signaling question 1: was there an appropriate interval between the index test and reference standard?
We expected urine specimens for LF-LAM and the reference standards to be obtained at the same time and answered ‘yes' for all studies
that meet this criterion, or if index and reference standard tests were performed on specimens collected no greater than seven days apart.
We chose seven days as a time period during which either treatment of tuberculosis or natural progression of tuberculosis without treat-
ment could impact test results. We answered ‘no' if specimens were collected for index and reference standard tests greater than seven
days apart, and ‘unclear' if we could not tell.
Signaling question 2: did all patients receive the same reference standard?
We answered ‘yes' if all participants in the study received the reference standard to confirm tuberculosis; ‘no' if not all patients received
the reference standard to confirm tuberculosis, and ‘unclear' if we could not tell.
Signaling question 3: were all patients included in the analysis?
We determined the answer to this question by comparing the number of participants enrolled in the study with the number of participants
included in the two-by-two tables. We answered ‘yes' if all participants enrolled in the study were tested with results presented and ac-
counted for. We answered ‘no' if participants meeting enrolment criteria were not tested or results were not presented, and ‘unclear' if
we could not tell.
Judgements for ʽRisk of bias' assessments:
If we answered all signalling questions for a domain "yes", then we judged risk of bias as "low".
If we answered all or most signalling questions for a domain "no", then we judged risk of bias as "high".
If we answered only one signalling question for a domain "no", we discussed further the "risk of bias" judgement.
If we answered all or most signalling questions for a domain "unclear", then we judged risk of bias as "unclear".
If we answered only one signalling question for a domain "unclear", we discussed further the "risk of bias" judgement for the domain.
Appendix 7. Statistical appendix
We list here the OpenBUGS program used to fit the bivariate meta-analysis models for estimating the accuracy of the index test. In the
subsections below, we first describe the likelihood and prior distribution for the model followed by the OpenBUGS program.
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As is usual with Bayesian models, initial values must be provided for all unknown parameters. We selected three independent sets of initial
values for the parameters using the in-built ModelGenInits() function within OpenBUGS. The Gelman-Rubin statistic within the OpenBUGS
program was used to assess convergence. We did not observe any convergence problems for the analyses presented. We treated the first
10,000 iterations as burn-in iterations and dropped them. We obtained summary statistics based on a total of 150,000 iterations resulting
from the three separate chains.
A. Estimation of index test accuracy
Notation: in the i-th study the cells in the cross-tabulation between the index and reference tests are denoted by TPi, FPi, TNi, FNi. The
sensitivity in i-th study is denoted by sei and the specificity by spi.
We denote the Binomial probability distribution with sample size N and probability p as Binomial(p,N), the Bivariate Normal probability
distribution with mean vector µ and variance-covariance matrix TAU as BVN(mu, TAU), the univariate Normal distribution with mean m and
variance tau2 by N(m, tau2) and the Uniform probability distribution between a and b by Uniform(a,b). Note that logit refers to log odds.
Likelihood:
Within studies:
TPi ˜ Binomial(TPRi, TPi + FNi), and
FPi ˜ Binomial(FPRi, TNi + FPi)
Between studies:
The bivariate vector (logit(TRPi), logit(FPRi)) ˜ BVN(mu = (mu1, mu2), TAU) where
TAU is a 2 X 2 matrix with entries
TAU[1,1] = variance of logit(TPRi) = tau12,
TAU[2,2] = variance of logit(FPRi) = tau22 and
TAU[1,2] = TAU[2,1] = covariance between logit(TPRi) and logit(FPRi) = rho × tau1 × tau2
and rho is the correlation between logit(TPRi) and logit(FPRi) across studies.
The pooled sensitivity is given by 1/(1+exp(-mu1)), and the pooled specificity is given by 1/(1+exp(-mu2)).
Prior distributions:
mu1 and mu2 ˜ N(m=0, tau2=4),
rho ˜ Uniform(-1, 1)
(1/ tau12) and (1/ tau22) ˜ Gamma(shape=2, rate=0.5)
A.1 OpenBUGS program for estimating a bivariate hierarchical meta-analysis model for sensitivity and specificity of the index test.
Observed data must be provided for L (the number of studies), and TP, FN, FP and TN in each study.
--------------------------------------------------------------------------------------------------------------------------------
model {
for(i in 1:L) { ## L is the number of studies in the Meta-analysis
# Likelihoood
pos[i]<-TP[i]+FN[i]
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neg[i]<-TN[i]+FP[i]
TP[i] ˜ dbin(TPR[i],pos[i])
FP[i] ˜ dbin(FPR[i],neg[i])logit(TPR[i]) <- l[i,1]
logit(FPR[i]) <- -l[i,2]se[i] <- TPR[i]
sp[i] <- 1-FPR[i]
l[i,1:2] ˜ dmnorm(mu[1:2], T[1:2, 1:2])
}
# Prior Distributions
mu[1] ˜ dnorm(0,0.25)
mu[2] ˜ dnorm(0,0.25)
T[1:2,1:2]<-inverse(TAU[1:2,1:2])
# Between-study variance-covariance matrix
TAU[1,1] <- tau[1]*tau[1]
TAU[2,2] <- tau[2]*tau[2]
TAU[1,2] <- rho*tau[1]*tau[2]
TAU[2,1] <- rho*tau[1]*tau[2]
# prec is the between-study precision in the logit(sensitivity) and logit(specificity)
# rho is the correlation between logit(sensitivity) and logit(specificity) across studies
prec[1] ˜ dgamma(2,0.5)
prec[2] ˜ dgamma(2,0.5)
rho ˜ dunif(-1,1)
tau[1]<-pow(prec[1],-0.5)
tau[2]<-pow(prec[2],-0.5)
# Pooled sensitivity and specificity
Pooled_S<-1/(1+exp(-mu[1]))
Pooled_C<-1/(1+exp(-mu[2]))
}
# Predicted sensitivity and specificity in a new study
l.new[1:2] ˜ dmnorm(mu[],T[,])
sens.new <- 1/(1+exp(-l.new[1]))
spec.new <- 1/(1+exp(-l.new[2]))
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}
# An R function (SROC_BUGS) for creating a joint summary plot of sensitivity and specificity of the index test
# using results from the OpenBUGS program above can be found in the DTAplots R package
# available for download at https://www.nandinidendukuri.com/software/diagnostic-meta-analysis
Appendix 8. Summary plot of LF-LAM sensitivity and specificity for tuberculosis detection in symptomatic
participants.
Figure 12.
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Figure 12.   Summary plot of LF-LAM sensitivity and specificity for tuberculosis detection in symptomatic
participants. The blue circles represent individual study estimates for sensitivity and specificity for the studies
among symptomatic participants. The size of the circle is proportional to the sample size of the study. The filled
black circle is the pooled estimate for sensitivity and specificity. The solid red line marks the 95% credible region
around the summary estimate, the dashed red line marks the 95% prediction region.
 
Appendix 9. Summary plot of LF-LAM sensitivity and specificity for tuberculosis detection in unselected
participants.
Figure 13.
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Figure 13.   Summary plot of LF-LAM sensitivity and specificity for tuberculosis detection in unselected participants.
The blue circles represent individual study estimates for sensitivity and specificity for the studies among unselected
participants. The size of the circle is proportional to the sample size of the study. The filled black circle is the pooled
estimate for sensitivity and specificity. The solid red line marks the 95% credible region around the summary
estimate, the dashed red line marks the 95% prediction region.
 
Appendix 10. Unselected participants with CD4 > 200 and CD4 ≤ 200
Figure 14.
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Figure 14.   Forest plots of LF-LAM sensitivity and specificity for tuberculosis against a microbiological reference
standard for studies among unselected participants, by CD4 strata (CD4 > 200 and CD4 ≤ 200) and health setting. The
individual studies are ordered by decreasing sensitivity. TP = True Positive; FP = False Positive; FN = False Negative;
TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure
shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).
 
Appendix 11. Unselected participants with CD4 > 100 and CD4 ≤ 100
Figure 15.
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Figure 15.   Forest plots of LF-LAM sensitivity and specificity for tuberculosis against a microbiological reference
standard for studies among unselected participants, by CD4 strata (CD4 > 100 and CD4 ≤ 100) and health setting. TP =
True Positive; FP = False Positive; FN = False Negative; TN = True Negative. Between brackets are the 95% confidence
interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study
(blue square) and its 95% CI (black horizontal line)
 
Appendix 12. Characteristics of studies among children with HIV
 
Study Country Age of enrolment Presence of tuberculo-
sis symptoms?
Setting Tuberculo-
sis preva-
lence % (n/
N)
Percent chil-
dren with ad-
vanced or
severe im-
munosup-
pression
Kroidl
2015
Tanzania 6 weeks to 14 years, median
8.8 years (IQR 3.9 to 9.5)a
Tuberculosis symptoms Outpa-
tient
40% (12/30 65%
LaCourse
2018a
Kenya ≤ 12 years, median 24 months
(IQR 13 to 58)
Irrespective of tuberculo-
sis symptoms
Inpatient 7% (9/130) 70%
Nicol 2014 South
Africa
≤ 15 years, median 42.5
months (IQR 19.1 to 66.3)*
Tuberculosis
symptoms
Inpatient
and out-
patient
22% (23/160) 53%
 
Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
96
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
 
aFor all participants, including HIV-positive and HIV-negative children.
IQR: interquartile range.
W H A T ' S   N E W
 
Date Event Description
9 October 2019 New citation required but conclusions
have not changed
We included 15 studies in this review update: nine new studies
and six studies from the original review (Shah 2016) that met the
inclusion criteria. The findings in this update are consistent with
those reported previously (Shah 2016).
9 October 2019 New search has been performed A new search was performed. The review authors identified 15
unique studies, integrating nine new studies to six of those in-
cluded in the previous Cochrane Review (Shah 2016). We used
the terminology of lateral flow urine lipoarabinomannan assay
(LF-LAM). The Alere Determine™ TB LAM Ag assay was the on-
ly LF-LAM test commercially available at the time of the review.
New tests coming into the market, such as the FujiLAM, was not
commercialized nor with any published data as of May 2018).
We evaluated performance of LF-LAM only at grade 1 on the up-
date reference scale card (scale of 1 to 4) equivalent to grade 2
on the old reference scale card (scale 1 to 5). We evaluated LF-
LAM accuracy against a microbiological reference standard and
did not include analysis against a composite reference standard.
We grouped the analysis by studies among ‘Symptomatic' and
‘Unselected' participants instead of the previous terminology
of ‘Diagnosis' and ‘Screening'. We changed the QUADAS judge-
ments for some of the previously included studies.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
DiOerences between review and review update
To further investigate for heterogeneity in data, we carried out additional subgroup analyses for the following CD4 strata: CD4 > 200; CD4
> 100 and CD4 101 to 200 cells/µL. We also performed a subgroup analysis by tuberculosis prevalence in the study population (pre-test
probability). In the review, we also estimated the predicted sensitivity and specificity in a future study together with their 95% credible
intervals (CrIs), which we did not mention in the protocol.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Biomarkers  [urine];  CD4 Lymphocyte Count;  HIV Seropositivity  [*complications];  Lipopolysaccharides  [*urine];  Point-of-Care Systems;
  Randomized Controlled Trials as Topic;  Sensitivity and Specificity;  Tuberculosis  [*diagnosis];  Tuberculosis, Pulmonary  [diagnosis]
MeSH check words
Adult; Humans
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